

# CUMULATIVE INDEX 2000

## Volume 84

January	RISK FACTOR MODIFICATION FOR CARDIAC DISEASE, pages 1-303
March	OBESITY, pages 305-518
May	INHERITED DISEASES OF THE PANCREAS, pages 519-767
July	ADOLESCENT MEDICINE, pages 769-1058
September	ADVANCES IN GASTROENTEROLOGY, pages 1059-1355
November	ANTIBIOTIC THERAPY, PART I, pages 1357-1530

Note: Page numbers of article titles are in **boldface** type

- Abdomen, excess fat in, risks associated
  - with, 394
  - versus mortality, 319, 425-426
- infections in, fluoroquinolones in, 1455-1456
- pain in, diagnostic criteria for, 1314
- in irritable bowel syndrome, 1247-1249
- psychiatric disorders with, 1319-1320
- Abstinence, as contraception, 910
- Abuse, sexual and physical, functional gastrointestinal disease in, 1321-1322
- Acanthosis nigricans, in polycystic ovary syndrome, 865-866
- Acetaminophen, hepatotoxicity of, 1292-1293
- Achalasia, treatment of, botulinum toxin injection in, 1064
- Achilles tendon, Sever's disease affecting, 1005
- Acinar cells, endocytosis inhibition in, in cystic fibrosis, 659-660
- Acinetobacter* infections, antibiotic combinations in, 1372
- Acitretin, hepatotoxicity of, 1301, 1303
- Acne, **811-828**
  - causes of, 811-814
  - clinical manifestations of, 814-815
  - definition of, 811
  - evaluation of, 815
  - myths about, 816
  - patient education on, 816-818
  - pomade, 815
  - treatment of, 816-825
  - follow-up in, 823-824
  - referral in, 824-825
  - selection of, 823
  - systemic, 821-823
  - topical, 818-821
- Acupuncture, in irritable bowel syndrome, 1253
- Acyclovir, in genital herpes infections, 884
- Adapalene, in acne, 820
- Adenocarcinoma, of pancreas, hereditary. See *Hereditary pancreatic adenocarcinoma*.
- Adenoma, colorectal. See *Colorectal polyps*.
- Adenomatous polyposis coli gene, 1164
- Adipocytes, metabolism in, 364-366
  - size of, insulin resistance and, 369
  - tumor necrosis factor- $\alpha$  production in, 369-370
- Adipose tissue. See *Fat, body*.
- Adiposity, index of, 318
- Adjuvant therapy, for hereditary pancreatic adenocarcinoma, 755-757
- Adnexal torsion, pelvic pain in, 1013-1014
- Adolescents, **769-785**
  - acne in, **811-828**
  - anxiety in, 891-897
  - asthma in, 829-842
  - characteristics of, 789-790
  - chronic pelvic pain in, **1009-1025**
  - cognition in, 774-775, 791
  - communication with, 1033
  - depression in, 778, 897-902
  - developmental changes in, 774-775

Adolescents (*Continued*)

- eating disorders in, **1027-1049**
- fatigue in, 845-849
- fibromyalgia in, 974-980
- headache in, 842-845
- health statistics for, 777-778
- health visits for, 769-770, 778-783
- historical complaints about, 788-789
- idealism in, 790-791
- immunization for, 783
- juvenile rheumatoid arthritis in, 967-974
- life stages in, 770, 775
- media effects on, 796-801, 804-805, 937-938
- menstrual disorders in, **851-868**
- mortality in, 777, 900
- narcissism in, 790-791
- new millennium issues in, 792
- parenting for, 805-806
- peer groups of, 790, 936
- prevention solutions for, 801-807
- puberty in, 771-774
- rationale for medical specialty, 771
- resiliency development in, 806-807
- rites of passage for, 789
- school support for, 806, 957-959, 973-974
- sexual activity in. *See Sexual activity, in adolescents.*
- sociocultural changes affecting, 775-777
- sports injuries in, **983-1007**
- turmoil in, 791-792
- violence in, 792-794, 797-798, 803-804
- Adrenal gland, congenital hyperplasia of, amenorrhea in, 862
- Adrenocorticotrophic hormone, altered response of, in fibromyalgia syndrome, 976
- Age, obesity and, 307-308, 316-317
  - bariatric surgery decisions, 486
  - versus energy expenditure, 354-355
- Agency for Health Care Policy and Research, smoking cessation guidelines of, 66-70
- Agoraphobia, 894
- Albumin levels, in nutritional assessment, 1210
- Albuterol, in asthma, 837-838, 840
- Alcohol, energy content of, 348
  - energy density of, 406
  - metabolism of, 349
- Alcohol use, in adolescents, consequences of, 944-945
  - developmental issues in, 932-934
  - media influence on, 799-801, 937-938
  - predictive factors for, 939-940
  - protective factors for, 938-939
  - risk factors for, 934-938
  - statistics on, 796, 930
- pancreatitis in, cancer risk in, versus hereditary pancreatitis, 567-569
- triglyceride levels and, 107-108
- Aloe, in constipation, 1241
- Alosetron, in irritable bowel syndrome, 1253
- Alpha-blockers, in hypertension, 10-11
- Alzheimer's disease, treatment of, hepatotoxicity in, 1290
- Ambulatory pH monitoring, in gastroesophageal reflux disease, 1142-1144
- Amdinocillin, synergy of, 1395
- Amenorrhea, 860-865
  - clinical manifestations of, 860-862
  - evaluation of, 863-864
  - in eating disorders, 1046-1047
  - in polycystic ovary syndrome, 865-866
  - treatment of, 864-865
- American Heart Association, Step I and Step II diets of, 96-99
- Amino acids, supplementation with, in nutritional therapy, 1222
- Aminoaciduria, in hereditary pancreatitis, 522
- Aminoglycosides, pharmacodynamics of, 1435-1439
  - resistance to, in enterococcal infections, 1475, 1479
  - synergy of, clinical uses for, 1399-1400
- Aminosaliclates, in inflammatory bowel disease, 1110-1111, 1118-1119
- Amiodarone, hepatotoxicity of, 1300
- Amitriptyline, in fibromyalgia syndrome, 978-979
- Amoxicillin, in chlamydial infections, 874
  - in *Helicobacter pylori* infections, 1127-1128
  - synergy of, 1398
- Amoxicillin/clavulanic acid, hepatotoxicity of, 1293-1294
- Amphetamine abuse, in adolescents, 932, 949
- Amphetamines, in obesity, 463-464
- Ampicillin, synergy of, 1395
  - clinical uses for, 1399-1400
- Amplification Refractory Mutation System, in *ras* gene mutation detection, in hereditary pancreatic adenocarcinoma, 724
- Amygdala, in anxiety, 892-893
- Amylase deficiency, in pancreatic dysfunction, 618
- Amylin, in hereditary pancreatic adenocarcinoma screening, 743
- Amyotrophic lateral sclerosis, treatment of, hepatotoxicity in, 1290
- Anabolic steroids, adolescent abuse of, 949-950
  - hepatotoxicity of, 1298
- Androgens, excess of, in polycystic ovary syndrome, 865-866

- hepatotoxicity of, 1298  
 in acne, 811-812  
 insensitivity to, amenorrhea in, 862  
 measurement of, in amenorrhea, 864  
 Anemia, in dysfunctional uterine bleeding, 858-859  
   sideroblastic, in Pearson's bone marrow syndrome, 617-618  
 Anesthetics, hepatotoxicity of, 1288  
 Angina, exertional, cardiac rehabilitation effects on, 254  
 Angiodysplasia, gastrointestinal, bleeding from, 1186-1187, 1190-1191, 1197  
 Angiogenesis, induction of, by gene therapy, in cardiovascular disease, 205  
 Angiography, of gastrointestinal bleeding, 1195  
   of hereditary pancreatic adenocarcinoma, 752-753  
 Angiotensin-converting enzyme inhibitors, hepatotoxicity of, 1300  
   in cardiovascular disease prevention, 272  
   in hypertension, 11-12  
 Angiotensin receptor blockers, in hypertension, 12-14  
 Angiotherapy, for gastrointestinal bleeding, 1198-1199  
 Ankle, Sever's disease of, 1005  
 Anorectum, cancer of. See *Colorectal cancer*.  
   intussusception of, 1245  
   manometry of, in constipation, 1237, 1239  
   transit time in, disorders of, 1233  
 Anorexia nervosa. See *Eating disorders*.  
 Anovulation, amenorrhea in, 864-865  
   dysfunctional uterine bleeding in, 855  
 Antacids, in gastroesophageal reflux disease, 1146  
 Antagonism, antibiotic, 1399  
 Anthropometry, in nutritional assessment, 1210  
 Anti-*Saccharomyces cerevisiae* antibody, in inflammatory bowel disease, 1109  
 Antiandrogens, hepatotoxicity of, 1299  
 Antibiotics. See also specific antibiotics.  
   antagonism of, 1399  
   antienterococcal. See *Enterococcal infections*.  
   combinations of, 1357-1389  
     advantages of, 1357  
     antagonism in, 1399  
     disadvantages of, 1357-1358  
     fluoroquinolones in, 1457  
     guidelines for, 1373-1374  
     in abdominal infections, 1373  
     in *Acinetobacter* infections, 1372  
     in bacteremia, 1372  
     in brucellosis, 1364  
     in *Enterobacter* infections, 1370  
     in enterococcal infections, 1362-1363  
     in gram-negative infections, 1364-1372  
     in gram-positive infections, 1358-1364  
     in *Klebsiella* infections, 1370-1371  
     in legionellosis, 1366-1367  
     in listeriosis, 1363-1364  
     in *Pseudomonas aeruginosa* infections, 1367-1369  
     in *Serratia* infections, 1371-1372  
     in staphylococcal infections, 1358-1361  
     in streptococcal infections, 1361-1362  
     justification for, 1391  
     microbiologic basis for, 1358  
     pharmacologic basis for, 1358  
     resistance development and, 1358  
     synergy in. See *Antibiotics, synergy of*.  
   cross-resistance in, 1410  
   empiric, in diarrhea, 1272-1273  
   hepatotoxicity of, 1293-1296  
   in acne, 819-822  
   in animal feeds, resistance development and, 1414  
   in hospital formularies, 1416-1417, 1419-1420  
   pharmacodynamics of, 1431-1446  
     concentration-dependent, 1435-1440  
     concentration-independent, 1432-1435  
     gatifloxacin versus levofloxacin comparison, 1440-1444  
     historical background of, 1431-1432  
     Monte Carlo simulation of, 1440  
   resistance to, 1407-1430  
     acquired, 1408  
     by class, 1413-1414  
     control of, 1416-1419  
     corrective measures for, 1419-1421  
     data interpretation in, 1409-1411  
     determinants of, 1411-1416  
     dosage and, 1409  
     importance of, 1407  
     in combinations, 1358  
     in enterococcal infections, 1472-1487  
       aminoglycosides, 1475, 1478, 1481-1482  
       b-lactams, 1473-1475, 1481  
       glycopeptides, 1478, 1482-1487  
       multidrug, 1479  
     natural, 1408  
     organisms not involved in, 1407-1408, 1412-1413  
     prevention of, 1421  
     substitution in, 1419-1421  
     terminology of, 1408-1409  
   restricted use of, 1416-1417  
   selection of, computer-assisted, 1417-1418  
   susceptibility drift in, 1411  
   synergy of, 1358, 1391-1405  
     cell wall activity in, 1393-1394  
     clinical examples of, 1399-1402

- Antibiotics (*Continued*)  
 common pathways in, 1394-1397  
 in vitro testing of, 1392  
 mechanisms of, 1392-1399  
 resistance inhibition in, 1398-1399  
 tissue concentrations of, resistance development and, 1415-1416  
 transitional therapy with, 1457-1460
- Antibodies, monoclonal, in inflammatory bowel disease, 1114-1115, 1119  
 to p53 protein mutants, in hereditary pancreatic adenocarcinoma, 729
- Anticoagulants, gastrointestinal bleeding due to, 1197-1198  
 in cardiovascular disease prevention, 171-174, 271
- Anticonvulsants, hepatotoxicity of, 1288-1289
- Antidepressants, hepatotoxicity of, 1289  
 in anxiety, 896-897  
 in depression, 901  
 in fibromyalgia syndrome, 978-979  
 in irritable bowel syndrome, 1252, 1322-1323
- Antiepileptic drugs, hepatotoxicity of, 1288-1289
- Antiestrogens, hepatotoxicity of, 1299
- Antifungal agents, hepatotoxicity of, 1295-1296
- Antineutrophil cytoplasmic antibodies, in inflammatory bowel disease, 1109
- Antioxidants, abnormal, in hereditary pancreatitis, 523-525  
 cardiovascular effects of, 108-110, 239-249  
 carotenoids, 110, 241-242  
 vitamin C, 110, 239-241  
 vitamin E, 108-109, 242-246  
 in colorectal cancer prevention, 1166
- Antiplatelet agents, in cardiovascular disease prevention, 163-171  
 aspirin, 164-167, 271  
 clopidogrel, 168-170  
 glycoprotein IIb/IIIa inhibitors, 170-171  
 outcome of, 271  
 ticlopidine, 167-168
- Antipsychotics, hepatotoxicity of, 1290  
 in anxiety, 896-897
- Antithyroid drugs, hepatotoxicity of, 1297-1298  
 inhibitory indices of, 1414  
 kill ratios of, 1414
- Antiviral agents, hepatotoxicity of, 1296
- Anxiety, 891-897  
 acceptance, 892  
 clinical features of, 893  
 conditions co-existing with, 895  
 diagnosis of, 893-895  
 in esophageal motility disorders, 1317-1319  
 in irritable bowel syndrome, 1315-1316  
 pathophysiology of, 892-893  
 performance, 892  
 prevalence of, 894-895  
 self-preserved use of, 891-892  
 sexual appeal, 892  
 signal, 891  
 treatment of, 896-897
- APC gene, in colorectal cancer, 1164, 1174
- Apheresis, in hypercholesterolemia, 37-38
- Apnea, sleep, in obesity, 314, 364, 397-398
- Apophyseal injuries, 987-988
- Appendicitis, pelvic pain in, 1015
- Arachidonic acid and metabolites, imbalance of, in cystic fibrosis, 661-662
- Arginine supplementation, in nutritional therapy, 1222
- Argon plasma coagulation, endoscopic, 1064-1065
- Arthritis, in morbid obesity, 486  
 rheumatoid. *See Rheumatoid arthritis.*
- Aspiration pneumonia, in enteral feeding, 1214-1215
- Aspirin, hepatotoxicity of, 1291  
 in cardiovascular disease prevention, 164-167, 271
- Asthma, 829-842  
 classification of, 831-832  
 clinical features of, 832  
 epidemiology of, 829-830  
 exercise-induced, 838  
 in gastroesophageal reflux disease, 1140-1141  
 management guidelines for, 830  
 patient education on, 830-831  
 treatment of, 831, 833-842
- Ataxia telangiectasia, pancreatic cancer and, 670
- Atherosclerosis, in chronic infection, 123-148  
 C-reactive protein in, 124-127, 149-161  
*Chlamydia pneumoniae*, 127-136  
 cytomegalovirus, 136-139  
*Helicobacter pylori*, 139-141  
 pathogenesis of, 127  
 periodontal, 141-142  
 predictive value of, 124-127  
 inhibition of, antioxidants in, 108-110, 239-249  
 promotion of, smoking in, 64
- Athletic injuries. *See Sports injuries.*
- Attention-deficit hyperactivity disorder, substance abuse in, 933-934
- Atypical ductal hyperplasia, of pancreas, 707-708, 714
- Azathioprine, in inflammatory bowel disease, 1112-1113, 1119
- Azelaic acid, in acne, 821
- Azithromycin, in chlamydial infections, 874

- Bacteremia, antibiotic combinations in, 1372-1373  
*Pseudomonas aeruginosa*, 1367-1368
- Bacterial vaginosis, in adolescents, 882-883
- Bacteroides* infections, sexually transmitted, 882-883
- Balloon tamponade, for variceal bleeding, 1188
- Band ligation, for variceal bleeding, 1189
- Banding, gastric, in obesity, 483-484
- Barbiturate abuse, in adolescents, 948-949
- Bariatric surgery, 477-489  
 age considerations in, 486  
 contraindications for, 480  
 expectations from, 480-481  
 future of, 487-488  
 goals of, 485-486  
 obesity morbidity and, 478-479  
 patient selection for, 479-480  
 procedures for, 481-485  
   combined gastric restriction and dumping physiology, 484  
   gastric restriction, 483-484  
   global malabsorption, 482-483  
   selective maldigestion and malabsorption, 484-485  
 quality of life issues in, 486-487  
 reoperative, 487
- Barium studies, in colorectal cancer and polyps, 1168  
 in constipation, 1235  
 in gastroesophageal reflux disease, 1141-1142  
 in gastrointestinal bleeding, 1196
- Barrett's esophagus, 1152-1158  
 adenocarcinoma in, 1155, 1157-1158  
 asymptomatic, 1140  
 causes of, 1153  
 definition of, 1152-1153  
 diagnosis of, 1152-1153  
 dysplasia in, 1157-1158  
 endoscopy of, 1062-1063, 1155-1156  
 epidemiology of, 1153-1154  
 long-segment, 1152-1153  
 short-segment, 1152-1153  
 treatment of, 1156-1158
- Barrier contraception methods, 910-913, 921-922
- Basal ganglia, in anxiety, 892-893
- Basal metabolic rate, 348  
 in nutritional requirement determination, 1211-1212
- Beclomethasone, in asthma, 839
- Behavioral issues. See also *Sexual activity; Substance abuse; Violence*.  
 in fibromyalgia syndrome, 976-977  
 in rheumatoid arthritis, 973
- Behavioral therapy, for anxiety, 896  
 for constipation, 1243-1244  
 for obesity, 441-461. See also *Diet; Exercise and physical activity*.  
 cognitive restructuring in, 446  
 components of, 444-446  
 drugs with, 453-454  
 goals of, 442-443  
 hallmarks of, 443-444  
 in primary care, 454-457  
 long-term, 448-450  
 results of, 446-448  
 self-monitoring in, 444-445  
 theories of, 426-427  
 versus pharmacologic treatment, 450-452  
 for smoking cessation, 71-73
- Belching, in gastroesophageal reflux disease, 1140
- Benzodiazepines, in anxiety, 896-897
- Benzoyl peroxide, in acne, 818-819
- Benzphetamine, in obesity, 464
- Beta-blockers, in cardiovascular disease prevention, 271  
 in hypertension, 8-10
- Beta-carotene, cardiovascular effects of, 110, 241-242
- Bicarbonate secretion, in pancreas, 641-655  
 chloride independence and, 645-646  
 cystic fibrosis transmembrane regulator in, 643-646, 648-649, 652  
 inhibition of, in cystic fibrosis, 622, 659-660  
 model for, current, 641-646  
   proposed, 646-652  
   physiology of, 641-644  
 sodium dependence and, 644-645
- Bile, *ras* gene mutation detection in, in hereditary pancreatic adenocarcinoma, 725-726
- Bile acids, malabsorption of, diarrhea in, 1268  
 sequestrants for, in hypercholesterolemia, 33-34
- Bile ducts, vanishing, drug-induced, 1282
- Biliary cirrhosis, in cystic fibrosis, 614-615  
 primary, 1095-1096
- Biliopancreatic bypass, partial, in obesity, 484-485
- Binge eating disorder. See *Eating disorders*.
- Biofeedback, in constipation, 1244
- Biologic therapy, for inflammatory bowel disease, 1114-1115
- Biopsy, intestinal, in inflammatory bowel disease, 1108  
 liver, in steatohepatitis, 1090-1091  
 pancreatic, in hereditary adenocarcinoma, 713-714
- Bipolar disorder, 899
- Birth control. See *Contraception; Oral contraceptives*.
- Bisacodyl, in constipation, 1242
- Bismuth subsalicylate, in *Helicobacter pylori* infections, 1127-1128

- Bitololol, in asthma, 840
- Blackheads, 813
- Bleeding, gastrointestinal, **1183-1208**
  - lower, 1191-1199
    - angiography in, 1195
    - causes of, 1196-1198
    - clinical features of, 1191-1192
    - colonoscopy in, 1193-1194
    - epidemiology of, 1191
    - evaluation of, 1192-1196
    - mortality in, 1192
    - radionuclide scans in, 1194-1195
    - treatment of, 1198-1199
    - versus upper, 1192
  - small intestinal, 1190-1191
  - upper, 1183-1190
    - causes of, 1184
    - epidemiology of, 1183-1184
    - in peptic ulcer disease, 1060, 1184-1187
    - nonvariceal, 1184-1187
    - variceal, 1061, 1187-1190
    - versus lower, 1192
  - uterine, dysfunctional, 855-859
- Bloating, in irritable bowel syndrome, 1247-1249
- Blood, occult, testing for, in colorectal cancer screening, 1169-1172
  - in diarrhea, 1266
- Blood pressure, high. *See Hypertension.*
- measurement of, in obese persons, 396
- Body composition, determination of, 394-395
  - of adolescents, sports injuries and, 986
  - versus mortality, 318-322, 424
- Body fat-free mass index, versus mortality, 318-319
- Body image, anxiety about, 892
  - decreased, in puberty, 773
  - distortion of, in eating disorders, 1038
- Body mass index, calculation of, 394
  - formula for, 318
  - genetic factors in, 334-335
  - in lean people, 394
  - in nutritional assessment, 1210
  - in obesity definition, 305-306, 419-420
  - versus mortality, 315, 424-426
- Body weight. *See Weight.*
- Bone, disorders of, in Shwachman-Diamond syndrome, 616-617
  - fractures of, physeal, 987-991
  - stress, 993
  - growth of, sports injuries and, 988
  - infections of, fluoroquinolones in, 1456-1457
  - loss of, in eating disorders, 1045-1046
- Bone marrow dysfunction, in Shwachman-Diamond syndrome, 616
- Botulinum toxin injection, for achalasia, 1064
- Bradycardia, in eating disorders, 1044
- Brain tumors, headache in, 842
- BRCA2 gene mutations, pancreatic cancer and, 669-670, 693
- Breast, cancer of, in obesity, 313-314
  - pancreatic cancer with, 669-670
  - risk of, in hormone replacement therapy, 187-189
  - development of, 772-773
- Bridge therapy, for rheumatoid arthritis, 972
- Bromfenac, hepatotoxicity of, 1291
- Bronchodilators, in asthma, 833-836, 838
- Brucellosis, antibiotic combinations in, 1364, 1402
- Budesonide, in asthma, 833, 839
  - in inflammatory bowel disease, 1112
- Bulimia nervosa. *See Eating disorders.*
- Bupropion, in anxiety, 896-897
  - in smoking cessation, 75-76
- C-reactive protein, atherosclerosis and, 124-127, **149-161**
  - clinical applications of, 151-157
  - management of, 155-157
  - pathogenesis of, 150-151
- Caffeine, in obesity, 471
- Calcaneus, Sever's disease of, 1005
- Calcium, in colorectal cancer prevention, 1166-1167
  - in pancreatic bicarbonate secretion, 643
  - in premature trypsinogen activation, acute pancreatitis, 557-560
- Calcium channel blockers, in hypertension, 14
- Calcium polycarbophil, in constipation, 1240-1241
- Calories, in diet. *See Energy intake.*
- requirements for, determination of, 1211-1212
- Calorimetry, in energy expenditure measurement, 351-353
  - indirect, in nutritional requirement determination, 1211-1212
- Cancer, breast, in obesity, 313-314
  - pancreatic cancer with, 669-670
  - risk of, in hormone replacement therapy, 187-189
- cholangiocarcinoma, endoscopic retrograde cholangiopancreatography in, 1072-1073
- colorectal. *See Colorectal cancer.*
- esophageal, endoscopic ultrasonography in, 1077-1078
- Helicobacter pylori* infections and, 1131
- in Barrett's esophagus, 1155, 1157-1158
- gastric, *Helicobacter pylori* infections and, 1131

- gastrointestinal, bleeding from, 1187  
 obstruction in, endoscopic stent placement for, 1063-1064, 1066-1067  
 in obesity, 313-314  
 nutrition in, 1221-1222  
 pancreatic, celiac neurolysis in, 1077  
   endoscopic ultrasonography in, 1075-1077  
   epidemiology of, 566  
   hereditary. *See Hereditary pancreatic adenocarcinoma.*  
   risk factors for, 566  
 Carbamazepine, hepatotoxicity of, 1288  
 Carbohydrates, dietary, triglyceride levels and, 107  
   energy content of, 348  
   energy density of, 405-406  
   in weight-loss diets, 402  
   in weight-maintenance diets, 411-412  
   malabsorption of, diarrhea in, 1268-1269  
   metabolism of, cardiac rehabilitation effects on, 258  
   storage of, 349  
 Carbonic anhydrase, in pancreatic bicarbonate secretion, 643  
 Carcinoembryonic antigen, in hereditary pancreatic adenocarcinoma screening, 742-744  
 Carcinoid syndrome, diarrhea in, 1268  
 Cardiac arrhythmias, in eating disorders, 1044-1045  
   in smoking, 65  
 Cardiac rehabilitation, 251-265  
   cost-effectiveness of, 284  
   definition of, 251-252  
   outcome of, 270-271  
     blood lipid levels, 255-257  
     blood pressure, 258  
     carbohydrate metabolism, 258  
     economic, 260-261  
     exercise tolerance, 254  
     morbidity, 253  
     mortality rate, 252-253  
     quality of life, 258-260  
     symptom-related, 254  
     weight, 257  
   participation in, 260  
 Cardiotoxicity, of fluoroquinolones, 1463-1464  
 Cardiovascular disease, risk factor modification for, 267-278  
   anticoagulants in, 171-174, 271  
   antioxidants in, 108-110, 239-249  
   antiplatelet agents in, 163-171, 271  
   C-reactive protein elevation, 124-127, 149-161  
   cardiac rehabilitation in, 251-265, 270-271, 284  
   chronic infection, 123-148  
   cost-effectiveness of, 279-297  
   diabetes mellitus, 81-93, 220  
   evidence for lack of implementation, 272-273  
   evidence supporting, 268-272  
   genetic therapy in, 199-213  
   hormone replacement in, 181-198, 272, 284-286  
   hypercholesterolemia. *See Hypercholesterolemia.*  
   hyperhomocysteinemia, 215-237  
   hypertension. *See Hypertension.*  
   lipids and. *See Hypercholesterolemia; Hyperlipoproteinemia; Hypertriglyceridemia.*  
   obesity, 95-122, 257, 270-271  
   smoking. *See Tobacco use.*  
   strategies for, 273-275  
 Cardiovascular drugs, hepatotoxicity of, 1300-1301  
 Carotenoids, cardiovascular effects of, 110, 241-242  
 Cartilage, growth, injuries of, 987-991  
 Cascara, in constipation, 1241  
 Cathepsin B, in zymogen activation, in acute pancreatitis, 555-557  
 Catheters, intravascular, for gene therapy delivery, in cardiovascular disease, 205  
 Cationic trypsinogen. *See Trypsinogen, cationic.*  
 CDKN2 gene mutations, in familial atypical multiple mole melanoma syndrome, 668-669  
 CDP571, in inflammatory bowel disease, 1114-1115  
 Cefepime, pharmacodynamics of, 1433-1434  
 Cefoperazone, synergy of, 1398  
 Ceftazidime, pharmacodynamics of, 1433-1434  
 Celecoxib, gastroduodenal effects of, 1339-1340  
 Celiac neurolysis, endoscopic, in pancreatic cancer, 1077  
 Cephalosporins, in gonorrhea, 875  
   in pelvic inflammatory disease, 1013  
   synergy of, 1395-1396  
 Cerebrovascular disease, in hyperhomocysteinemia, 224  
 Cervical cap, 912  
 Cervix, ectropion of, sexually transmitted disease transmission and, 873  
 CFTR. *See Cystic fibrosis transmembrane regulator.*  
 CFTR gene, mutations of, 598-599, 610  
   arachidonic acid metabolism abnormalities in, 662  
   in chronic idiopathic pancreatitis, 621-631  
   data supporting, 623-626  
   diagnosis of, 627-628

- CFTR gene (*Continued*)  
 future research on, 628  
 genotype-phenotype correlations in, 622-623  
   in mild cystic fibrosis, 622-623  
   pathogenesis of, 622, 626-627  
   physiologic testing of, 625  
   in heterozygotes, 601  
   in homozygotes, 601-602  
   mechanistic classification of, 599-601  
   severity of, 611-612  
   polymorphisms of, 600-601  
 Chemotherapy, for colorectal cancer, 1177-1178  
   for hereditary pancreatic adenocarcinoma, 756-757  
 Chest pain, noncardiac, in gastroesophageal reflux disease, 1139  
   psychiatric disorders with, 1317-1319  
 Childhood obesity, energy expenditure in, 355-356  
   treatment and prevention of, 494-496  
   school-based, 496-501  
*Chlamydia pneumoniae* infections, chronic, atherosclerosis and, 127-136  
*Chlamydia trachomatis* infections, in adolescents, 873-874, 876-879  
*Chlorella pyrenoidosa* nutritional supplement, in fibromyalgia syndrome, 980  
 Chloride, conductance of, cystic fibrosis transmembrane regulator in, 633-639  
   in pancreatic bicarbonate secretion, 645-646, 651-652  
 Chloride:bicarbonate cotransporter, in pancreatic bicarbonate secretion, 651  
 Chlorpromazine, hepatotoxicity of, 1290  
 Cholangiocarcinoma, endoscopic retrograde cholangiopancreatography in, 1072-1073  
 Cholangitis, sclerosing, endoscopic retrograde cholangiopancreatography in, 1073-1074  
 Choledocholithiasis, endoscopic ultrasonography of, 1078-1079  
 Cholestasis, drug-induced, 1282, 1284  
 Cholesterol, dietary, 101-102  
   disturbances of, in obesity, 309-311  
   excess levels of. *See Hypercholesterolemia.*  
   high-density lipoprotein, diet effects on, 106-107  
   low levels of, 48-50, 87-88  
   low-density lipoprotein, diet effects on, 101-106  
 Cholesterol-lowering agents, hepatotoxicity of, 1299-1300  
 Cholestyramine, in hypercholesterolemia, 33-34  
 Chronic fatigue syndrome, 845-849  
 Chronic illness, in adolescents, 776-777  
 Chronic pelvic pain, 1009-1025  
   cyclic, 1015-1016  
   gynecologic, 1009-1014, 1016-1019  
   noncyclic, gynecologic, 1016-1019  
   nongynecologic, 1019-1021  
   nongynecologic, 1014-1015, 1019-1021  
   nonorganic, 1021-1023  
 Chylomicrons, excess of, 44-45  
 Cigarette smoking. *See Tobacco use.*  
 Cimetidine, in gastroesophageal reflux disease, 1147  
 Ciprofloxacin, 1452  
   chemical structure of, 1450  
   in gonorrhea, 875-876  
 Cirrhosis, biliary, in cystic fibrosis, 614-615  
   primary, 1095-1096  
 Clarithromycin, in *Helicobacter pylori* infections, 1127-1128  
 Clavicle, atraumatic osteolysis of, in sports, 993  
 Clavulanic acid, synergy of, 1398  
 Clinafloxacin, 1452-1453  
 Clindamycin, in acne, 820  
   in bacterial vaginosis, 883  
   in pelvic inflammatory disease, 1013  
 Clofibrate, in hypercholesterolemia, 35-36  
 Clopidogrel, in cardiovascular disease prevention, 168-170  
 Coagulation disorders, in diabetes mellitus, cardiovascular disease and, 90  
   in hyperhomocysteinemia, 228-229  
 Cocaine use, in adolescents, 946-947  
 Coffee, low-density lipoprotein levels and, 105  
 Cognitive development, in adolescents, 774-775, 791  
 Cognitive therapy, for anxiety, 896  
   for depression, 900-901  
   for gastrointestinal disorders, 1322  
   for obesity, 446  
 Colectomy, in colorectal cancer, 1176-1177  
   in constipation, 1244-1245  
   in gastrointestinal bleeding, 1199  
   in inflammatory bowel disease, 1116  
 Colestipol, in hypercholesterolemia, 33-34  
 Colitis, ulcerative. *See Inflammatory bowel disease.*  
 Colon, cancer of. *See Colorectal cancer.*  
   irritable. *See Irritable bowel syndrome.*  
   motor patterns in, 1233  
   polyps of. *See Colorectal polyps.*  
   transit time in, disorders of, 1233  
 Colonoscopy, 1068-1070  
   after cancer treatment, 1178  
   after polypectomy, 1173  
   complications of, 1168  
   in bleeding, 1193-1194  
   in cancer, diagnostic, 1168  
   in constipation, 1234-1235



- in diarrhea, 1263, 1268
- in gastrointestinal bleeding, 1198
- in inflammatory bowel disease, for cancer surveillance, 1175-1176
- rapid preparation for, 1193-1194
- Colorectal cancer, **1163-1182**
  - adenoma-carcinoma sequence in, 1167-1168
  - bleeding from, 1197
  - clinical features of, 1169
  - diagnosis of, 1168
  - environmental causes of, 1164-1167
  - family history of, 1173-1175
  - hereditary nonpolyposis, 1174
  - in inflammatory bowel disease, 1118
  - in Lynch syndromes, 1174
  - in obesity, 314
  - metastasis from, 1177-1178
  - molecular genesis of, 1164
  - NSAID preventive effects in, 1330
  - pancreatic cancer with, 669
  - prevention of, primary, 1164-1167
    - secondary, 1167-1168
  - recurrent, 1178
  - risk factors for, 1163
  - screening for, 1169-1172
  - staging of, 1176-1177
  - surveillance for, after curative therapy, 1178
    - after polypectomy, 1173
    - in inflammatory bowel disease, 1175-1176
    - treatment of, 1176-1178
- Colorectal polyps, bleeding from, 1197
- cancer development in, 1167-1168
- diagnosis of, 1168
- family history of, 1173-1175
- screening for, 1169-1172
- sigmoidoscopy in, 1068-1069
- surveillance of, 1173
- treatment of, 1172-1173
- types of, 1167
- Comedogenesis, 813
- Complementary therapy, for fibromyalgia syndrome, 980
- Computed tomography, of hereditary pancreatic adenocarcinoma, preoperative, 751
  - surveillance and screening, 713, 720
- Condoms, 870-871, 910-912
- Condylomata acuminata, 885-887
- Confidentiality, in adolescent medicine, 779-780, 872
- Congenital adrenal hyperplasia, amenorrhea in, 862
- Connective tissue, homocysteine interactions with, 228
- Consent, in adolescent medicine, 778-779
- Constipation, **1231-1246**
  - age considerations in, 1233-1334
  - causes of, 1232
  - chronic functional, definition of, 1231
  - economic issues in, 1232
  - epidemiology of, 1231
  - evaluation of, 1234-1239
  - in cystic fibrosis, 613-614
  - in irritable bowel syndrome, 1247-1249, 1252-1253
  - pain in, 1019-1020
  - pathophysiology of, 1232-1234
  - risk factors for, 1232
  - treatment of, drugs in, 1242
    - in problematic patients-, 1243
    - laxatives in, 1240-1242
    - severe, 1243-1245
    - uncomplicated, 1237, 1240
- Contraception, **907-925**. See also *Oral contraceptives*.
  - abstinence, 910
  - adolescent issues in, 921-923
  - assessment for, 908-909
  - barrier methods, 870-871, 910-913, 921-922
  - cervical cap, 912
  - condoms, 870-871, 910-912
  - diaphragm, 912
  - emergency, 919-921
  - future, 921-922
  - hormonal, emergency, 919-921
    - implants, 918
    - injectable, 916-918
    - oral. See *Oral contraceptives*.
  - in disease protection, 870-871
  - need for, 907-908
  - spermicides, 913
  - Coping, with rheumatoid arthritis, 973
  - Coronary artery disease, in obesity, 313, 319
    - risk factor modification for. See *Cardiovascular disease, risk factor modification for*.
- Corticosteroids, in asthma, 833-836, 838-839, 841
  - in inflammatory bowel disease, 1110, 1118-1119
  - in rheumatoid arthritis, 972
- Corticotropin-releasing factor, in irritable bowel syndrome, 1251
- Cost-effectiveness, of cardiac rehabilitation, 260-261
  - of cardiovascular disease prevention, **279-297**
    - behavioral modification, 282-284
    - cardiac rehabilitation, 284
    - hormone replacement therapy, 284-286
    - hyperlipidemia reduction, 288-293
    - hypertension control, 286-287
    - methods for, 280-281
- Cough, in gastroesophageal reflux disease, 1140-1141

- Counseling, in hereditary pancreatic disease, 577, 584-585  
 in obesity, on physical activity, 427-430  
 in pancreatic cancer, 671-672
- Crime, in adolescents, 792-794  
 media influence on, 797-798  
 prevention of, 801-807
- Critical illness, nutrition in, 1221
- Crohn's disease. *See Inflammatory bowel disease.*
- Cromolyn, in asthma, 835-836, 838
- Cyanoacrylate glue, for variceal bleeding, 1189
- Cyclic adenosine monophosphate, in cystic fibrosis transmembrane regulator function, 633-639  
 in pancreatic bicarbonate secretion, 650
- Cyclosporine, in inflammatory bowel disease, 1113-1114, 1118-1119
- Cyclothymia, 899
- Cyproterone acetate, hepatotoxicity of, 1299
- Cystic fibrosis, 609-617  
 age of manifestation appearance in, 612-613  
*CFTR* gene in. *See CFTR gene.*  
 classic, 601  
 clinical features of, 612-615  
   gastrointestinal, 613-614  
   hepatobiliary, 614-615  
   pancreatic, 613, **657-664**  
 genotype-phenotype relationships in, **597-607**, 611-612  
*CFTR* gene mutations in, 598-599  
   clinical implications of, 601-603  
   in mild variant, 622-623  
   mechanistic classification of, 599-601  
 epithelial electrolyte transport and, 598  
   variability of, 597-598  
 heterozygous, 601  
 homozygous, 601-602  
 male infertility in, 602, 623  
 non-*CFTR* gene mutations in, 603  
 pancreatic dysfunction in, **657-664**  
   acinar cell endocytosis inhibition in, 659-660  
   intraductal plug obstruction in, 657-659  
   membrane lipid imbalance in, 661-662  
   sibling concordance of, 601-602  
 pancreatic enzyme supplementation in, 611  
 pancreatitis in, *CFTR* gene in, 541  
 pathophysiology of, 610-611  
 survival rate in, 612  
 sweat gland dysfunction in, 597-598  
 Cystic fibrosis transmembrane regulator, defects of, 598-599  
   distribution of, 598  
   function of, 598-599, 622  
   gene of. *See CFTR gene.*  
   in bicarbonate secretion, 643-646, 648-649, 652  
   structure of, 598-599  
   trafficking of, regulation of, **633-639**
- Cysts, in acne, 814  
 ovarian, 855, 1014
- Cytomegalovirus infections, atherosclerosis and, 136-139
- Dapsone, hepatotoxicity of, 1295
- DCC gene, in colorectal cancer, 1164
- Death, in adolescents, causes of, 777  
 in depression, 900
- Decompression surgery, in hereditary pancreatitis, 526
- Deep venous thrombosis, in hyperhomocysteinemia, 225
- Defense system, anxiety as, 891-892
- Dehydroepiandrosterone sulfate, in acne, 812
- Denial, in eating disorders, 1038-1039
- Depomedroxyprogesterone acetate, as injectable contraceptive, 916-918
- Depression, in adolescents, 778, 897-902  
 acuity of, 902  
 biologic basis of, 897-898  
 diagnosis of, 898-900  
 melancholic, 898  
 suicide possibility assessment in, 902  
 treatment of, 900-902  
 in esophageal motility disorders, 1317-1319  
 in irritable bowel syndrome, 1316-1317
- Deuterium-labeled water method, for energy expenditure measurement, 351-353
- Dexfenfluramine, in obesity, 464-466, 469
- Diabetes mellitus, cardiovascular disease in, **81-93**  
 dyslipidemia and, 85-88  
 hyperglycemia and, 81-84  
 hyperhomocysteinemia in, 220  
 hyperinsulinemia and, 84  
 hypertension and, 88-90  
 insulin resistance and, 84-85  
 procoagulant state and, 90  
 smoking and, 90  
 in cystic fibrosis, 613  
 in hereditary pancreatitis, 520-521  
 in obesity, 311, 368-373  
 in polycystic ovary syndrome, 865-866  
 pancreatic cancer and, 670  
 treatment of, in steatohepatitis, 1092
- Diaphragm, 912
- Diarrhea, **1259-1274**

- classification of, 1259-1260
- definition of, 1259
- differential diagnosis of, 1260-1261
- endocrine, 1268
- evaluation of, 1261-1272
  - acute, 1263-1264
  - chronic, 1263, 1265-1271
  - fatty, 1270-1272
  - history in, 1261-1262
  - inflammatory, 1269-1270
  - physical examination in, 1262
  - watery, 1266-1269
- iatrogenic, 1261-1262
- in enteral feeding, 1214
- in irritable bowel syndrome, 1247-1249, 1252-1253
- osmotic, 1268-1269
- secretory, 1266-1268
- traveler's, 1262, 1272
- treatment of, 1272-1273
- Diclofenac, hepatotoxicity of, 1291
- Dicyclomine, in irritable bowel syndrome, 1252
- Diet, antioxidants in. *See Antioxidants.*
- elemental, for inflammatory bowel disease, 1218
- energy balance and, 341
- for colorectal cancer prevention, 1165-1166
- for eating disorders, 1036-1037, 1039
- for gastroesophageal reflux disease, 1145
- for hypercholesterolemia reduction, 29-30
- for irritable bowel syndrome, 1251-1252
- for obesity. *See Obesity, dietary modification in.*
- for weight loss, 339-340, 401-418
  - carbohydrate-restricted, 402
  - education on, community-based, 502-504
  - school-based, 495-501
  - energy density of, 405-406
    - constant, 409
    - food intake and, 406-411
  - factors affecting intake, 406, 408-411
  - fat-restricted, 402
  - historical background of, 402
  - hunger control in, 413-415
  - low-calorie, 403
  - National Institutes of Health guidelines for, 402-404
  - optimal calorie level for, 403
  - optimal composition for, 403
  - portion-controlled, 451
  - self-monitoring of, 444-445
  - very low-calorie, 403
  - very-low-calorie, 447-448
  - with total energy intake restrictions, 405
  - without total energy intake restrictions, 404-405
- for weight maintenance, 403-404, 411-413
- hereditary pancreatic adenocarcinoma and, 686
- hyperhomocysteinemia related to, 219
- Dieulafoy's lesions, bleeding from, 1187
- Diphenoxylate, in irritable bowel syndrome, 1253
- Distal intestinal obstruction syndrome, in cystic fibrosis, 613-614
- Disulfiram, hepatotoxicity of, 1301
- Diuretics, abuse of, in eating disorders, 1029
- hepatotoxicity of, 1300-1301
- Diverticulosis, bleeding in, 1196-1197
- DNA analysis, in hereditary pancreatic adenocarcinoma. *See Molecular markers, for hereditary pancreatic adenocarcinoma.*
- in trypsinogen mutation detection, 535-536
- DNA liposomes, for gene therapy, for cardiovascular disease, 203-204
- Docusates, in constipation, 1241
- Doubly labeled water method, for energy expenditure measurement, 351-353
- Down's syndrome, energy expenditure in, 357
- Doxycycline, in acne, 821
- in chlamydial infections, 874
- in pelvic inflammatory disease, 878-879, 1013
- Drug(s), abuse of. *See Alcohol use; Substance abuse.*
- constipation due to, 1233
- gastrointestinal bleeding due to, 1197-1198
- in obesity, 463-476
  - adherence to, 453-454
  - amphetamines, 463-464
  - behavioral treatment with, 450-454
  - clinical use of, 471-473
  - dexfenfluramine, 464-466, 469
  - fenfluramine-phentermine, 450-453, 466-467
  - fluoxetine, 467
  - historical aspects of, 463-465
  - orlistat, 451, 469-471
  - phentermine, 450-453, 466-467
  - sibutramine, 451-452, 467-469, 471, 473
- liver disease due to, 1275-1311
  - Alzheimer's disease drugs, 1290
  - amyotrophic lateral sclerosis drugs, 1290
  - anesthetics, 1288
  - antibiotics, 1293-1296
  - anticonvulsants, 1288-1289
  - antidepressants, 1289
  - antiparkinsonian drugs, 1290

## Drug(s) (Continued)

- antipsychotics, 1290
- antithyroid drugs, 1297-1298
- cardiovascular drugs, 1300-1301
- cholesterol-lowering agents, 1299-1300
- clinical features of, 1280-1287
- diagnosis of, 1275-1277
- gastrointestinal drugs, 1301
- herbal remedies, 1301-1302
- hormones, 1298-1299
- idiosyncratic, 1301-1302
- incidence of, 1275
- intrinsic, 1301-1302
- mechanisms of, 1277-1278
- natural history of, 1287
- nonsteroidal anti-inflammatory drugs, 1291-1293
- oral hypoglycemic agents, 1296-1297
- pathologic spectrum of, 1280
- prognosis for, 1287
- risk factors for, 1277, 1279
- stimulants, 1289
- metabolism of, nicotine effects on, 66
- weight gain from, 393
- Ductal adenocarcinoma, of pancreas, hereditary. See *Hereditary pancreatic adenocarcinoma*.
- Dumping physiology, in bariatric surgery, 484
- Duodenoscopy. See *Esophagogastroduodenoscopy*.
- Dysbetalipoproteinemia, familial, 48
- Dysfunctional uterine bleeding, 855-859
- Dyslipidemia. See also *Hypercholesterolemia*; *Hyperlipoproteinemia*; *Hypertriglyceridemia*.
  - in obesity, 309-311, 375-378
- Dysmenorrhea, 852-855, 1015-1016
- Dyspepsia, functional, diagnostic criteria for, 1314-1315
  - psychiatric disorders with, 1320-1321
  - NSAID-associated, treatment of, 1333-1334
- Dysthymia, 898-899
- Eating disorders, 393, **1027-1049**
  - amenorrhea in, 1046-1047
  - clinical features of, 1031-1036
  - definitions of, 1027-1029
  - diagnostic criteria for, 1027-1029
  - epidemiology of, 1029-1030
  - laboratory tests in, 1034-1036
  - medical concerns in, 1044-1047
  - myocardial impairment in, 1044-1045
  - obesity in, 393
  - osteoporosis in, 1045-1046
  - pathogenesis of, 1030-1031
  - prognosis for, 1043-1044
  - treatment of, 1036-1043
    - hospitalization in, 1042-1043
    - in early stage, 1036-1037
    - in moderate stage, 1037-1041
    - interdisciplinary team approach to, 1041-1042
    - principles of, 1027
    - referral for, 1040-1041
- Ecstasy designer drug use, in adolescents, 949
- Ectropion, cervical, sexually transmitted disease transmission and, 873
- Edema, refeeding, in eating disorder treatment, 1044-1045
- Elbow injuries, in throwing sports, 996-997
- Elderly persons, constipation in, 1234
- Electrocoagulation, for peptic ulcer bleeding, 1186
- Electrolyte transport, in cystic fibrosis, 598
- Embolization, in gastrointestinal bleeding, 1198-1199
- Endocarditis, antibiotic combinations in, enterococcal, 1362-1363, 1399-1400
  - Listeria monocytogenes*, 1363-1364
  - Pseudomonas aeruginosa*, 1368
  - staphylococcal, 1360
- Endocytosis, of acinar cells, inhibition of, in cystic fibrosis, 659-660
- Endometriosis, chronic pelvic pain in, 1018-1019
  - dysmenorrhea in, 853-855
- Endometrium, abnormal sloughing of, 855-859
  - cancer of, in obesity, 314
- Endoscopic retrograde cholangiopancreatography, 1070-1074
  - complications of, 1074
  - in ascending cholangitis, 1071-1072
  - in hereditary pancreatic adenocarcinoma surveillance and screening, 710-711, 713
  - in malignant biliary obstruction, 1072-1073
  - in retained common bile duct stone removal, 1071-1072
- Endoscopy, gastrointestinal, **1059-1083**. See also specific techniques, e.g., *Colonoscopy*.
  - in bleeding, upper tract, 1184-1187
  - in feeding tube placement, 1213
  - in inflammatory bowel disease, 1108-1109
  - of colon. See *Colonoscopy*; *Sigmoidoscopy*.
  - of pancreaticobiliary tract, 1070-1074
  - of small intestine, 1065, 1068, 1190-1191
  - of upper tract. See *Esophagogastroduodenoscopy*.

- selective tissue ablation in, 1064-1065  
 ultrasonography with, 1075-1079  
 ultrasonography with, in hereditary pancreatic adenocarcinoma, 710-713, 720, 751
- Endothelium, homocysteine interactions with, 226-228
- Enemas, in constipation, 1242, 1244
- Energy, storage of, 349-350
- Energy balance, components of, 348-350  
 definition of, 349  
 negative, 349  
 positive, 349  
 regulation of, 347  
 environmental effects on, 336-337  
 small changes in, 347
- Energy density, of weight-loss diet, 405-406, 414  
 constant, 409  
 food intake and, 406-411  
 macronutrients, 405-406  
 water effects on, 406-407, 410
- Energy expenditure, concept of, 350  
 factors influencing, 353-355  
 gender differences in, 355  
 historical aspects of, 350-351  
 in food intake, 348  
 in growth, 349  
 in physical activity, 348-349, 353, 358-359  
 measurement of, 351-353  
 obesity and, 355-359  
 postobese models of, 357-358  
 preobese models of, 357  
 total daily, secular trends in, 337-338, 359, 422, 492-493  
 types of, 348-349  
 versus age, 354-355
- Energy intake, definition of, 348  
 energy density effects on, 406-411  
 excess, environmental factors promoting, 338-340  
 optimal, in weight-loss diet, 403  
 reduced, in weight-loss diet, 405  
 unrestricted, in reduced-fat diet, 404-405  
 yearly, 347
- Energy metabolism. *See Energy balance; Energy expenditure; Energy intake.*
- Enoxacin, 1451
- Enteral nutrition. *See under Nutrition.*
- Enterobacter* infections, antibiotic combinations in, 1370
- Enterococcal infections, **1471-1494**  
 antibiotics in, combinations of, 1362-1363, 1484-1487  
 resistance mechanisms in, 1473-1479  
 synergy of, 1399-1400  
 with aminoglycoside resistance, 1481-1482  
 with  $\beta$ -lactam resistance, 1481  
 with glycopeptide resistance, 1482-1487  
 without acquired resistance, 1479-1481
- Bacteriology of, 1471-1473  
 clinical features of, 1472-1473  
 transmission of, 1473
- Enterococcus faecalis*, antibiotic synergism and, 1393
- Enteroscopy, 1065, 1068, 1190-1191
- Environmental factors, in colorectal cancer, 1164-1167  
 in *Helicobacter pylori* infections, 1133  
 in hereditary pancreatic adenocarcinoma, 686  
 in obesity, 335-343  
 cumulative effect of, 341  
 diet, 339-340  
 energy balance regulation and, 336-337  
 low levels of physical activity, 337  
 preventive changes in, 341-343  
 promoting excess energy intake, 338-340  
 public health interventions and, 492-493  
 total daily energy expenditure trends, 337-338  
 in physical activity program, 435
- Enzymatic mutation detection methods, in trypsinogen mutation detection, 535-537
- Enzyme immunoassay, for hepatitis C virus, 1088
- Ephedra, in obesity, 471
- Ephedrine, in obesity, 471
- Epiphyseal plate, injuries of, 987-991
- Epithelia, electrolyte transport through, in cystic fibrosis, 598
- Erythromycin, hepatotoxicity of, 1294  
 in acne, 820-821  
 in chlamydial infections, 874
- Esophagitis, bleeding from, 1187  
 in gastroesophageal reflux disease, treatment of, 1150
- Esophagogastroduodenoscopy, 1059-1064, 1066-1067  
 in achalasia, 1064  
 in Barrett's esophagus, 1062-1063, 1155-1156  
 in bleeding, 1060-1061, 1196  
 in reflux disease, 1142  
 in stenting of obstruction, 1063-1064, 1066-1067  
 technique for, 1059-1060
- Esophagography, in gastroesophageal reflux disease, 1141-1142
- Esophagus, adenocarcinoma of, risk of, in Barrett's. *See Barrett's esophagus.*  
 cancer of, endoscopic ultrasonography in, 1077-1078

Esophagus (*Continued*)

- Helicobacter pylori* infections and, 1131
- in Barrett's esophagus, 1155, 1157-1158
- irritable, 1139, 1318
- Mallory-Weiss tears of, bleeding from, 1187
- motility disorders of, psychiatric disorders with, 1317-1319
- reflux disease of. See *Gastroesophageal reflux disease*.
- sphincters of, botulinum toxin injection into, 1064
- transient relaxation of, 1138
- weakness of, gastroesophageal reflux disease in, 1137-1138
- variceal bleeding in, 1061, 1187-1190
- Estrogens, formation of, in obesity, 313-314
- in oral contraceptives. See *Oral contraceptives*.
- secretion of, in puberty, 771-772
- therapy with. See also *Hormone replacement therapy*.
- hepatotoxicity of, 1298-1299
- in acne, 823
- in amenorrhea, 864-865
- in dysfunctional uterine bleeding, 858-859
- in testicular feminization, 862
- Etanercept, in inflammatory bowel disease, 1115
- in rheumatoid arthritis, 972
- Ethical issues, in genetic testing, in hereditary pancreatic disease, 586
- in nutritional therapy, 1224-1225
- Ethnic differences, in obesity, 308-309
- energy expenditure and, 357
- mortality and, 317-318
- Etretinate, hepatotoxicity of, 1301
- Eugonadotropic eugonadism, amenorrhea in, 862
- European Genetic Register of Hereditary Pancreatitis and Familial Pancreatic Cancer, genetic testing protocol of, 582-586
- Exercise and physical activity, bronchoconstriction in, 838
- energy expenditure in, 348-349, 353, 358-359
- in cardiac rehabilitation. See *Cardiac rehabilitation*.
- in eating disorders, 1039-1040
- in fibromyalgia syndrome, 978-979
- in obesity, 419-440, 445-446
- childhood, 495-501
- community-based programs for, 502-504
- health benefits of, 423-426
- history of, 392
- in weight-loss maintenance, 422-423
- lifestyle interventions in, 436-437
- mortality rates and, 424-426
- prevalence and, 419-420
- strategies for increasing, 426-437
- barriers to, 432-434
- behavioral, 426-427, 430-435
- counseling on, 427-430
- environmental cues in, 435
- goal setting, 431-432
- self-monitoring, 430-431
- trends in, 421-422
- versus other weight-loss interventions, 421
- versus stage of change, 429-430
- in patellofemoral syndrome, 1002
- in rheumatoid arthritis, 972-973
- in weight gain prevention, 422
- injuries in. See *Sports injuries*.
- low levels of, environmental factors promoting, 342
- obesity in, 337
- pelvic pain in, 1021
- versus weight, 355
- Familial adenomatous polyposis, 1174
- Familial atypical multiple mole melanoma syndrome, pancreatic adenocarcinoma and, 668-669
- Familial pancreatitis, versus hereditary pancreatitis, 519
- FAMMM (familial atypical multiple mole melanoma) syndrome, pancreatic adenocarcinoma and, 668-669
- Famotidine, in gastroesophageal reflux disease, 1147
- Fasting, in hereditary pancreatitis, 526
- Fat, body. See also *Abdomen, excess fat in*.
- cell size of, insulin resistance and, 369
- distribution of, in metabolic syndrome, 363-364, 366
- energy storage in, 349-350
- mass of, energy expenditure and, 353-355
- resting metabolic rate and, 353-354
- metabolism in, 364-366
- visceral versus subcutaneous, 364
- dietary, absorption of, inhibitors of, in obesity, 451
- energy content of, 348
- energy density of, 406-407
- food intake effects of, 406, 408-409
- in weight gain prevention, 412-413
- in weight-loss diets, restriction of, 402-405
- in weight-maintenance diet, 411-412
- low-density lipoprotein levels and, 102-104
- malabsorption of, diarrhea in, 1270-1272

- orlistat and, 451, 469-471
  - obesity and, 339-340
- Fatigue, in adolescents, 845-849
- in fibromyalgia syndrome, 974-975
- Fatty acids, essential, deficiency of, in cystic fibrosis, 662
- free. *See* Free fatty acids.
- in nutritional therapy, 1223
- Fatty liver, nonalcoholic, 1089-1092
- Felbamate, hepatotoxicity of, 1289
- Feminization, testicular, amenorrhea in, 862
- Fenfluramine, in obesity, 464
- Fenfluramine-phentermine, in obesity, 450-453, 466-467
- Fenofibrate, in hypercholesterolemia, 35-36
- Fetal occult blood testing, for colorectal cancer, 1169-1172
- for diarrhea, 1266
- Fialuridine, hepatotoxicity of, 1296
- Fiber, dietary, low-density lipoprotein levels and, 104-105
- Fibrates, in hypercholesterolemia, 35-36
- Fibroblast growth factor, promotion of, gene therapy in, 208-210
- Fibromyalgia syndrome, 974-980
  - behavioral aspects of, 976-977
  - causes of, 975
  - clinical features of, 974-975
  - diagnostic criteria for, 974
  - pathophysiology of, 975-976
  - prognosis for, 977-978
  - treatment of, 978-980
- Fight-or-flight response, 891
- Flavonoids, cardiovascular effects of, 110
- Flexibility, of adolescents, sports injuries and, 986-987
- Fluid therapy, for diarrhea, 1272
- for variceal bleeding, 1188
- Flunisolide, in asthma, 839
- Fluorescence in-situ hybridization, in *SMAD4* gene mutation detection, in hereditary pancreatic adenocarcinoma, 730
- Fluoroquinolones, **1447-1469**
  - chemical structures of, 1449-1450
  - complications of, 1460-1464
  - development of, 1447-1449, 1451-1453
  - generations of, 1451-1453
  - in abdominal infections, 1455-1456
  - in combination therapy, 1457
  - in enterococcal infections, 1484-1485
  - in joint infections, 1456-1457
  - in mycobacterial infections, 1457
  - in osteomyelitis, 1456-1457
  - in pneumonia, 1453-1455
  - in transitional therapy, 1457-1460
  - in urinary tract infections, 1456
  - mechanisms of action of, 1449, 1451
  - pharmacodynamics of, 1439-1440, 1449, 1451
  - tolerability of, 1460-1464
- 5-Fluorouracil, in hereditary pancreatic adenocarcinoma, 756
- Fluoxetine, in depression, 901
- in obesity, 467
- Flutamide, hepatotoxicity of, 1299
- Fluticasone, in asthma, 833, 839
- Fluvoxamine, in anxiety, 897
- Folic acid, hyperhomocysteinemia and, 226, 229-230
- Follicle-stimulating hormone, deficiency of, amenorrhea in, 860-861
- excess of, amenorrhea in, 860-862
- secretion of, in puberty, 771
- Food. *See* also Diet; Eating disorders; Nutrition.
- availability of, obesity and, 340
- intake of, energy expenditure in, 348, 354
- portion sizes of, obesity and, 340
- Fractures, epiphyseal, 987-991
- stress, in sports, 993
- Free fatty acids, blood concentration of, 365
- excess of, dyslipidemias in, 376-378
- in glucose production augmentation, 371-372
- in metabolic syndrome, experimental models of, 366-368
- lowering of, 367
- metabolism of, 364-366
- oxidation of, in skeletal muscle, glucose accumulation in, 368-369
- inhibition of, 368
- toxicity of, to liver, insulin extraction and, 371
- to pancreatic islets, 372-373
- vasoactivity of, 374-375
- Free radicals, in hereditary pancreatitis, 523-525
- Fundoplication, in gastroesophageal reflux disease, 1148-1150
- Furazolidone, in *Helicobacter pylori* infections, 1128
- G-protein-coupled second messengers, in pancreatic bicarbonate secretion, 643
- Gabexate mesilate, in hereditary pancreatitis, 526
- Gallbladder disease, endoscopic retrograde cholangiopancreatography in, 1070-1074
- in cystic fibrosis, 614-615
- Gardnerella vaginalis* infections, 882-883
- Garlic, low-density lipoprotein levels and, 105-106
- Gastric bypass, in obesity, 485
- Gastric lavage, in bleeding, 1185

- Gastric restriction procedure, in obesity, 483-484
- Gastritis, *Helicobacter pylori*. See *Helicobacter pylori* infections.
- Gastroduodenopathy, NSAID-associated, pathogenesis and pathology of, 1330-1332  
prevention of, 1336-1341  
risk factors for, 1332-1333  
treatment of, 1333-1335
- Gastroenteritis, pelvic pain in, 1015
- Gastroenterology, Barrett's esophagus, 1062-1063, **1137-1161**  
colorectal cancer. See *Colorectal cancer*.  
constipation, **1231-1246**  
diarrhea. See *Diarrhea*.  
drug-induced liver disease, **1275-1311**  
endoscopy. See *Endoscopy, gastrointestinal*; specific procedures.  
gastroesophageal reflux disease, 1129-1130, 1132, **1137-1161**  
gastrointestinal bleeding, **1183-1208**  
*Helicobacter pylori* infections, **1125-1136**, 1186  
hepatology. See *Liver*.  
inflammatory bowel disease. See *Inflammatory bowel disease*.  
irritable bowel syndrome, **1247-1257**, 1314-1317  
nonsteroidal anti-inflammatory drug-induced effects in. See *Nonsteroidal anti-inflammatory drugs, gastrointestinal effects of*.  
nutrition, **1209-1230**  
psychologic and psychiatric aspects of, 1251-1252, 1254, **1313-1327**
- Gastroesophageal reflux disease, **1137-1161**  
ambulatory pH monitoring in, 1142-1144  
Barrett's esophagus and, 1152-1158  
clinical features of, 1139-1141  
diagnosis of, 1139-1144  
endoscopy in, 1142  
extraesophageal manifestations of, 1140-1141  
*Helicobacter pylori* infections and, 1129-1130, 1132  
omeprazole test in, 1144  
pathophysiology of, 1137-1138  
radiography of, 1141-1142  
treatment of, 1144-1151  
algorithm for, 1151  
antacids in, 1146  
goals of, 1144  
histamine-receptor antagonists in, 1146-1147  
lifestyle changes in, 1145  
nonerosive, 1145-1150  
proton-pump inhibitors in, 1147-1148  
surgical, 1148-1150  
ulcerative/erosive, 1150
- Gastrointestinal disorders, fluoroquinolone-induced, 1463  
in cystic fibrosis, 613-614
- Gastrointestinal drugs, hepatotoxicity of, 1301
- Gastrojejunostomy, for enteral feeding, 1213-1214
- Gastroscopy. See *Esophagogastroduodenoscopy*.
- Gastrostomy, percutaneous endoscopic, for enteral feeding, 1213-1214
- Gatifloxacin, 1452  
chemical structure of, 1450  
pharmacodynamics of, 1440-1444
- Gemcitabine, in hereditary pancreatic adenocarcinoma, 756
- Gemfibrozil, in hypercholesterolemia, 35-36
- Gender differences, in energy expenditure, 355  
in obesity, 306-307
- Gene therapy, for cardiovascular disease, **199-213**  
animal models of, 205-206  
clinical experience with, 206-210  
vectors for, 199-205  
for hereditary pancreatitis, 542, 593-594
- Generalized anxiety disorder, diagnosis of, 893-894  
treatment of, 896-897
- Genetic factors, in acne, 813  
in hemochromatosis, 1092-1095  
in inflammatory bowel disease, 1107-1108  
in obesity, 334-335, 356-357, 393  
visceral, 364
- Genetic testing, in hereditary pancreatic disease, **575-587**  
applications of, 576-577  
benefits of, 578  
business issues in, 581-582  
cancer, 585-586, 671-672  
clinical issues in, 582  
counseling in, 577, 584-585  
ethical issues in, 586  
in children, 580, 585  
laboratory issues in, 580-581  
limitations of, 578-579  
nondisclosure in, 587  
pancreatitis, **575-588**, 627-628  
predictive issues in, 579-580, 584-585  
process of, 577  
protocol for, 582-586  
recruitment for, 586  
regulatory issues in, 580-581  
results reporting in, 586-587
- Genital herpes infections, in adolescents, 883-885
- Genital warts, 885-887
- Gentamicin, in pelvic inflammatory disease, 1013  
pharmacodynamics of, 1438



- GERD. See *Gastroesophageal reflux disease*.
- Global malabsorption technique, in obesity, 482-483
- Gluconeogenesis, versus free fatty acid concentrations, 371-372
- Glucose-fatty acid cycle, in skeletal muscle, in obesity, 368-369
- Glucose metabolism, 350
- abnormalities of, in obesity, 368-373
- Glutamine supplementation, in nutritional therapy, 1222
- Glycogen, energy storage in, 349-350
- Glycopeptides, resistance to, in enterococcal infections, 1478, 1482-1487
- Glycoprotein IIb/IIIa inhibitors, in cardiovascular disease prevention, 170-171
- Gonadotropin-releasing hormone, secretion of, in puberty, 771
- Gonorrhea, 874-879
- GP2 protein, in pancreatic duct plugs, in cystic fibrosis, 658-659
- Granulomatous hepatitis, drug-induced, 1283
- Grepafloxacin, 1452
- Growth, energy expenditure in, 349
- sports injuries and, 985-987
- Growth cartilage, injuries of, 987-991
- Growth factors and receptors, in hereditary pancreatic adenocarcinoma, 697-705
- in nutritional therapy, 1222
- Gun violence, in adolescents, 792-794
- media influence on, 797-798
- prevention of, 801-807
- Gymnast's wrist, 998-999
- Gynecologic disorders. See *Chronic pelvic pain*; *Menstrual cycle, disorders of*; *Sexually transmitted diseases*.
- HACEK group endocarditis, antibiotic synergy in, 1400
- HAIR-AN syndrome ( polycystic ovary syndrome), 865-866
- Hair follicles, obstruction of. See *Acne*.
- Hallucinogen use, in adolescents, 947-957
- Halothane, hepatotoxicity of, 1288
- Harris-Benedict equation, in nutritional requirement determination, 1211-1212
- Headache, 842-845
- HEADFIRST screening tool, for substance abuse, 951
- Heart, disease of, fen-phen-induced, 466-467
- fluoroquinolone toxicity to, 1463-1464
- transplantation of, hyperlipidemia in, 54-55
- Heartburn, in gastroesophageal reflux disease, 1139
- Heavy water method, for energy expenditure measurement, 351-353
- Height, of adolescents, 772-773
- sports injuries and, 985
- Helicobacter pylori* infections, **1125-1136**
- antibiotic synergy in, 1402
- asymptomatic versus clinical disease in, 1132-1133
- atherosclerosis and, 139-141
- diagnosis of, 1125-1126
- diseases caused by, 1125
- environmental factors in, 1133
- host factors in, 1133
- treatment of, 1126-1132
- antibiotics for, 1126-1129
- antisecretory therapy and, 1132
- combination, 1127-1128
- recommendations for, 1128
- with gastric metaplasia, 1131-1132
- with gastroesophageal carcinoma, 1131
- with gastroesophageal reflux disease, 1129-1130
- with peptic ulcer disease, 1186
- virulence factors in, 1132-1133
- Hematemesis, in gastrointestinal bleeding, 1184, 1188
- Hematologic abnormalities, in Shwachman-Diamond syndrome, 616
- Hemochromatosis, hereditary, 1092-1095
- Hemorrhoids, bleeding in, 1197
- Heparin, in cardiovascular disease prevention, 171-172
- in inflammatory bowel disease, 1115
- Hepatitis, chronic, drug-induced, 1283
- granulomatous, drug-induced, 1283
- in fatty liver, 1089-1092
- viral, 1085-1089
- Hepatitis B, chronic, 1085-1087
- Hepatitis C, chronic, 1087-1089
- Hepatocellular adenoma, drug-induced, 1287
- Hepatocellular injury, drug-induced, 1281
- Hepatology. See *Liver, diseases of*; *specific diseases*.
- Hepatotoxicity, of drugs. See *Drug(s), liver disease due to*.
- Herbal remedies, hepatotoxicity of, 1301-1302
- Hereditary nonpolyposis colorectal cancer, 1174
- pancreatic cancer with, 669
- Hereditary pancreatic adenocarcinoma, **665-675**
- age of onset of, 682-683, 685-686
- angiography in, 752-753
- ataxia telangiectasia and, 670
- biopsy in, 713-714

# Hereditary pancreatic adenocarcinoma

(Continued)

- breast cancer genes and, 669-670
- clinical features of, 670-671
- computed tomography of, in surveillance and screening, 713, 720
  - preoperative, 751
- counseling in, 671-672
- definition of, 670-671
- diabetes mellitus and, 670
- endoscopic retrograde cholangiopancreatography of, in surveillance and screening, 710-711, 713, 720
- endoscopic ultrasonography of, preoperative, 751
- surveillance and screening, 710-713, 720
- epidemiology of, 665
- familial aggregation in, 667
- familial atypical multiple mole melanoma syndrome and, 668-669
- genetic testing in, 585-586, 671-672
- genetics of, 666-670, **691-695**
- hereditary nonpolyposis colorectal cancer and, 669
- hereditary pancreatitis and, 669
- historical perspective of, 666
- inheritance of, **677-690**
  - age of onset and, 682-683, 685-686
  - environmental factors and, 686
  - historical perspective of, 677-678
  - segregation analysis in, 681-682, 687
  - study methods for, 679-682, 684
  - susceptibility and, 685
- laparoscopy of, preoperative, 752
- magnetic resonance imaging of, in surveillance and screening, 713, 720
  - preoperative, 752
- medullary, 693
- pathology of, 692-693, 713-714
- pathophysiology of, **697-705**
  - hereditary pancreatitis and, 700
  - integrative, 698-699
- Peutz-Jeghers syndrome and, 670
- positron emission tomography of, 753
- precursor lesion of, 707-708
- registry for, 672
- risk factors for, 708-709, 719, 740-741, 749-750
- screening for, 687, **719-738**
  - cost analysis of, **739-747**
  - indications for, 719-720
  - methods for, 721, 742-743
  - costs of, 744-745
  - molecular markers in, 721-732, 742-744
  - p16 gene mutations, 731-733
  - p53 gene mutations, 725, 727-730, 733
  - ras gene mutations, 721-726, 732, 743

SMAD4 gene mutations, 730-731, 733

- projected number of patients for, 741
- strategies for, 732-733
- surgical treatment of, 715, **749-759**
  - adjuvant therapy with, 755-757
  - preoperative staging in, 750-753
  - prophylactic, 755
  - resectability determination in, 750-753
  - strategies for, 753-755
- surveillance for, **707-718**
  - family history in, 709-710
  - history in, 709
  - individuals at risk for, 708-709
  - methods for, 708, 710-714
  - physical examination in, 709
  - prospective, 715
  - treatment indicated after, 715
- syndromes associated with, 709-710, 749-750
- syndromes of, 668-670
- tumor markers in, preoperative, 753
- Hereditary pancreatitis, **519-529, 531-547**
  - anomalies associated with, 521-522
  - cancer in, 669, 700
    - risk of, **565-573**
      - parent of origin, 570
      - versus alcoholic pancreatitis, 567-569
      - versus cancer in general population, 566
    - screening for, 571, **719-737, 739-759**
  - clinical features of, 520-521, 531-532
  - genetic testing in, **575-588, 627-628**
  - genetics of, 521-522. See also *Trypsinogen*.
    - proposed defects in, 522-525
  - heterogeneity in, 541
  - nonpenetrance of, 539-540
  - pancreatis-associated gene in, 542
  - pathophysiology of, early studies of, 522-525
  - pioneer studies of, 519-520
  - prevention of, genetic testing in, 577
  - treatment of, 525-526, **589-595**
    - gene therapy in, 542
  - trypsinogen abnormalities in. See *Trypsinogen*.
    - versus familial pancreatitis, 519
- Heroin use, in adolescents, 947
- Herpes simplex virus infections, in adolescents, 883-885
- HGE gene mutations, in hemochromatosis, 1092-1095
- Hirsutism, amenorrhea with, 864
  - in polycystic ovary syndrome, 865-866
- Histamine receptor antagonists, in gastroesophageal reflux disease, 1146-1147
- in NSAID-associated dyspepsia, 1333-1334, 1336

- in NSAID-associated ulcers, 1335
- in peptic ulcer disease, 1185-1186
- in variceal bleeding, 1188
- Home nutritional support, 1223-1224
- Homocysteinemia. See *Hyperhomocysteinemia*.
- Homocystinuria, inherited, cardiovascular disease and, 219
- Hormone replacement therapy, for coronary artery disease prevention, 181-198
  - cardiovascular effects of, 183-184
  - controversies over, 186-192
  - cost-effectiveness of, 284-286
  - in hypercholesterolemia, 30-31
  - outcome of, 272
  - risk factors and, 184-186
  - use statistics for, 181-183
  - hepatotoxicity of, 1298-1299
- Host factors, in *Helicobacter pylori* infections, 1133
- Huffing, in adolescents, 932, 948
- Human immunodeficiency virus infection, syphilis with, 880
- Human leukocyte antigens, in inflammatory bowel disease, 1107-1108
- Human papillomavirus infections, in adolescents, 885-887
- Humerus, proximal physeal injury of, 996
- Hunger, control of, in weight-loss diets, 413-415
- Hycosine, in irritable bowel syndrome, 1252
- Hydralazine, hepatotoxicity of, 1300
- Hydrocortisone, in chronic fatigue syndrome, 847
- Hydroxymethylglutaryl coenzyme A reductase inhibitors, in hypercholesterolemia, 31-33
- Hydroxychloroquine, in rheumatoid arthritis, 971
- Hyperandrogenism, in polycystic ovary syndrome, 865-866
- Hypercalcemia, hereditary pancreatitis and, 522-523
- Hypercholesterolemia, cardiac rehabilitation effects on, 255-257
  - in hypothyroidism, 51-52
  - in kidney disease, 52-54
  - in obesity, 309-310
  - in organ transplantation, 54-55
  - treatment of, 23-42
    - benefits of, 23-27
    - cost-effectiveness of, 288-293
    - dietary, 29-30
    - drug, 31-37
    - estrogen replacement in, 30-31
    - evaluation for, 27-28
    - guidelines for, 28-29
    - in diabetes mellitus, 86-87
    - nonpharmacologic, 37-38
    - outcome of, 268-270
- Hyperchylomicronemia, 44-45
- Hyperglycemia, cardiovascular disease and, 81-84
  - in pancreatic islet toxicity, in obesity, 372-373
- Hypergonadotropic hypogonadism, amenorrhea in, 860-862
- Hyperhomocysteinemia, cardiovascular disease and, 215-237
  - causes of, 218-221
  - cerebral, 224
  - circulating homocysteine forms in, 217
  - coronary artery, 221-224
  - deep venous thrombosis, 225
  - folic acid effects on, 226
  - metabolic pathway in, 216-217
  - methionine loading test in, 218
  - pathogenesis of, 226-229
  - peripheral, 224-225
  - research on, 229-230
  - treatment of, 229-230
  - vitamin B<sub>6</sub> effects on, 226
- Hyperinsulinemia, cardiac rehabilitation effects on, 258
  - cardiovascular disease and, 84
  - in obesity, 370-371
  - in polycystic ovary syndrome, 865-866
- Hyperlipidemia, treatment of, in steatohepatitis, 1092
- Hyperlipoproteinemia, 43-48. See also *Hypercholesterolemia*.
  - cardiac rehabilitation effects on, 255-257
  - in diabetes mellitus, 85-88
  - in hypothyroidism, 51-52
  - in kidney disease, 52-54
  - in organ transplantation, 54-55
  - treatment of, cost-effectiveness of, 288-293
    - outcome of, 268-270
- Hypersensitivity, visceral, in irritable bowel syndrome, 1250
- Hypertension, after myocardial infarction, 1-21
  - assessment of, 4-6
  - blood pressure diurnal variations and, 7-8
  - J-curve phenomenon and, 3-4
  - prognosis and, 1-2
  - silent ischemia in, 6-7
  - thrombolytic therapy and, 2-3
  - treatment of, 8-15
    - cardiac rehabilitation effects on, 258
    - in diabetes mellitus, cardiovascular disease and, 88-90
    - in obesity, 112-113, 311-313, 373-375
    - sibutramine-induced, 468-469
    - treatment of, after myocardial infarction, 8-15

- Hypertension (*Continued*)  
 cost-effectiveness of, 286-287  
 outcome of, 270
- Hypertriglyceridemia, diet effects on,  
 107-108  
 in diabetes mellitus, 85-86  
 in kidney disease, 52-54  
 in obesity, 311, 376-378  
 in organ transplantation, 54-55  
 treatment of, 43-48  
 cost-effectiveness of, 288-293  
 in diabetes mellitus, 87-88
- Hypnotherapy, in irritable bowel  
 syndrome, 1253-1254
- Hypogonadism, amenorrhea in,  
 hypergonadotropic, 860-862  
 hypogonadotropic, 861-862
- Hypogonadotropic hypogonadism,  
 amenorrhea in, 861-862
- Hypotension, orthostatic, in chronic  
 fatigue syndrome, 847
- Hypothyroidism, hyperlipidemia in, 51-52
- Ibuprofen, hepatotoxicity of, 1292
- Ileal bypass, in hypercholesterolemia, 37
- Ileoanal anastomosis, in inflammatory  
 bowel disease, 1116
- Imiquimod, in condylomata acuminata,  
 887
- Immunization, for adolescents, 783
- Immunohistochemistry, in gene mutation  
 detection, in hereditary pancreatic  
 adenocarcinoma, 727-728, 731
- Immunomodulators, in inflammatory  
 bowel disease, 1112-1116
- Immunonutrients, in nutritional therapy,  
 1223
- Implants, contraceptive, 918
- Indinavir, hepatotoxicity of, 1296
- Infections, chronic, atherosclerosis in. See  
*Atherosclerosis, in chronic infection.*  
 diarrhea in, 1269-1270  
 in enteral feeding, 1215  
 in parenteral feeding, 1216-1217
- Infertility, male, in cystic fibrosis, 602, 623
- Inflammation, in acne, 813  
 of pancreas, in cystic fibrosis, 661-662
- Inflammatory bowel disease, **1107-1124**  
 bleeding in, 1197  
 cancer in, 1118  
 surveillance for, 1175-1176  
 diagnosis of, 1108-1109  
 diarrhea in, 1269-1270  
 genetic factors in, 1107-1108  
 imaging of, 1108-1109  
 nutrition in, 1117-1118, 1218-1219  
 osteoporosis in, 1116-1117  
 pain in, 1020  
 smoking and, 1117  
 treatment of, 1110-1116, 1118-1119
- Infliximab, in inflammatory bowel disease,  
 1114, 1119
- Inhalant abuse, in adolescents, 932, 948
- Inhalers, for asthma drug delivery, 831,  
 833, 839-841
- Injection therapy, for peptic ulcer bleeding,  
 1186
- Injuries, sports. See *Sports injuries.*
- INK4<sup>pt</sup> protein. See *p16 protein.*
- Inspissated secretions, in pancreas, in  
 cystic fibrosis, 657-659
- Insulin excess, cardiac rehabilitation effects  
 on, 258  
 cardiovascular disease and, 84  
 in polycystic ovary syndrome, 865-866
- Insulin resistance. See also *Metabolic  
 syndrome.*  
 cardiovascular disease and, 84-85  
 in obesity, 311, 368-373  
 excess glucose production in, 371-372  
 hyperinsulinemia in, 370-371  
 pancreatic islet toxicity in, 372-373  
 skeletal muscle disorders in, 368-369
- Interferon alfa, in hepatitis B, 1086-1087  
 in hepatitis C, 1088-1089
- Interleukin(s), in inflammatory bowel  
 disease, 1115
- International Hereditary Pancreatitis Study  
 Group, cancer risk studies of, 567-570
- Interview, in adolescent health visit,  
 780-782
- Intestinal obstruction, in cystic fibrosis,  
 613-614
- Intraductal neoplasia, of pancreas, 707-708
- Intubation, for enteral feeding, 1212-1214
- Intussusception, rectal, 1245
- Ipratropium bromide, in asthma, 838, 841
- Ipsalazide, in inflammatory bowel disease,  
 1111
- Iron overload (hemochromatosis),  
 hereditary, 1092-1095
- Irritable bowel syndrome, **1247-1257**  
 clinical features of, 1247-1249  
 definition of, 1247  
 diagnosis of, 1251  
 diagnostic criteria for, 1314  
 epidemiology of, 1249  
 mechanisms of, 1249-1251  
 pain in, 1020  
 psychiatric disorders with, 1315-1317  
 subsets of, 1247-1248  
 treatment of, 1251-1254
- Isoniazid, hepatotoxicity of, 1295-1296
- Isotretinoin, in acne, 820, 822-823
- J-curve phenomenon, in blood pressure,  
 3-4

- Jaundice, in cystic fibrosis, 614-615  
 obstructive, endoscopic retrograde cho-  
 langiopancreatography in, 1073
- Jejunioileal bypass, in obesity, 482-483
- Jejunostomy, for enteral feeding, 1213-1214
- Johanson-Blizzard syndrome, 617
- Joint infections, fluoroquinolones in,  
 1456-1457
- Juvenile rheumatoid arthritis. *See*  
*Rheumatoid arthritis, juvenile.*
- Ketoconazole, hepatotoxicity of, 1295
- Kidney, dysfunction of, hyperhomo-  
 cysteinemia in, 219-220  
 hyperlipidemia in, 52-54  
 failure of, nutrition in, 1220  
 transplantation of, hyperhomocysteine-  
 mia in, 220  
 hyperlipidemia in, 54
- Klebsiella* infections, antibiotic combina-  
 tions in, 1370-1371
- Knee, sports injuries of, Osgood-Schlatter  
 disease, 1003  
 osteochondritis dissecans, 1003-1004  
 patellofemoral syndrome, 1000-1002  
 Sever's disease, 1005
- Koebnerization, in juvenile rheumatoid  
 arthritis, 968
- Labetalol, hepatotoxicity of, 1300
- b-Lactam antibiotics, pharmacodynamics  
 of, 1432-1435  
 resistance to, in enterococcal infections,  
 1473-1475, 1481
- b-Lactamase, inhibition of, as synergistic  
 mechanism, 1398-1399
- Lactase deficiency, diarrhea in, 1269
- Lactose intolerance, pain in, 1020
- Lactulose, in constipation, 1241
- Lansoprazole, in gastroesophageal reflux  
 disease, 1147-1148
- Laparoscopy, in chronic pelvic pain, 1018  
 in hereditary pancreatic adenocarci-  
 noma, 752
- Laser therapy, for gastrointestinal  
 bleeding, 1198
- Lavage, gastric, in bleeding, 1185
- Laxatives, abuse of, in eating disorders,  
 1029  
 in constipation, abuse of, 1241, 1266  
 economic aspects of, 1232  
 fiber-containing, 1240  
 types of, 1237  
 with onset of one to three days, 1240-  
 1241  
 with rapid onset, 1241-1242
- Lean body mass, 306, 394  
 resting metabolic rate and, 353
- LEARN Program for Weight Control*, 452-453
- Lefradafiban, in cardiovascular disease  
 prevention, 170
- Legionellosis, antibiotic combinations in,  
 1366-1367
- Leptin, insulin resistance and, 370
- Leukotriene inhibitors, in asthma, 833, 835,  
 837-838
- Leuprolide, in dysfunctional uterine  
 bleeding, 859  
 in endometriosis, 854-855
- Levofloxacin, 1440-1444, 1452
- Lifestyle modification, in gastroesophageal  
 reflux disease, 1145  
 in hypertension, 8  
 in obesity, 445-446  
 for physical activity, 436-437
- Ligase chain reaction, in sexually  
 transmitted disease testing, 887-888
- Ligation, of esophageal varices, 1061
- Limbic system, in anxiety, 892-893
- Linezolid, in enterococcal infections, 1486
- Lipase deficiency, in pancreatic dysfunc-  
 tion, 618
- Lipolysis, free fatty acid formation in, 365
- Lipoprotein(a), excess of, 50-51
- Lipoprotein(s). *See also Cholesterol.*  
 excess of. *See Hypercholesterolemia; Hyper-*  
*lipoproteinemia.*  
 in triglyceride transport, 44-45  
 very low density, excess of, in obesity,  
 376-377
- Lipoprotein lipase, action of, 364
- Liposomes, DNA, for gene therapy, for  
 cardiovascular disease, 203-204
- Listeriosis, antibiotic combinations in,  
 1363-1364
- Lithotripsy, in hereditary pancreatitis, 526
- Little Leaguer elbow, 996-997
- Little Leaguer shoulder, 996
- Liver, biopsy of, in steatohepatitis,  
 1090-1091  
 diseases of, **1085-1105**  
 drug-induced. *See Drug(s), liver disease*  
*due to.*  
 genetic screening in, 1093-1094  
 hemochromatosis, 1092-1095  
 in cystic fibrosis, 614-615  
 nonalcoholic steatohepatitis, 1089-1092  
 nutrition in, 1220  
 primary biliary cirrhosis, 1095-1096  
 variceal bleeding in, 1187  
 viral hepatitis, 1085-1089  
 failure of, drug-induced, 1281  
 insulin extraction by, free fatty acid ef-  
 fects on, 371  
 transplantation of, 1096-1100  
 donor organ shortage for, 1097-1099

- Liver (*Continued*)  
   in primary biliary cirrhosis, 1095  
   in steatohepatitis, 1092  
   outcomes of, 1099-1100
- Lomefloxacin, 1451
- Loperamide, in irritable bowel syndrome, 1252
- LSD (lysergic acid diethylamide) use, in adolescents, 947-957
- Lumbar spondylosis, in sports, 999-1000
- Luteinizing hormone, deficiency of, amenorrhea in, 860-861  
   excess of, amenorrhea in, 860-862  
   secretion of, in puberty, 771
- LY333328 (glycopeptide), in enterococcal infections, 1486
- Lynch syndromes, 1174
- Lysergic acid diethylamide (LSD) use, in adolescents, 947-957
- Lysosomal enzymes, in zymogen activation, in acute pancreatitis, 555
- Magnesium ingestion, diarrhea in, 1268-1269
- Magnetic resonance imaging, of hereditary pancreatic adenocarcinoma, in surveillance and screening, 713, 720  
   preoperative, 752
- Maldigestion and malabsorption, selective, in obesity, 484-485
- Mallory-Weiss tears, bleeding from, 1187
- Malnutrition, assessment of, 1210-1211  
   definition of, 1209  
   prevalence of, 1209
- Manometry, anorectal, in constipation, 1237, 1239
- Marijuana use, in adolescents, 930-931, 945-946
- Meal-induced thermogenesis, 348-349, 354
- Meconium ileus, in cystic fibrosis, 613
- Media influence, on adolescents, 796-801, 804-805, 937-938, 959-960
- Medroxyprogesterone acetate, as injectable contraceptive, 916-918  
   in amenorrhea, 864-865  
   in dysfunctional uterine bleeding, 859  
   in endometriosis, 1019
- Melancholic depression, 898
- Melanoma, in familial atypical multiple mole melanoma syndrome, pancreatic adenocarcinoma and, 668-669
- Melena, in gastrointestinal bleeding, upper, 1184
- Menarche, 771-772, 851-852  
   absence of. *See Amenorrhea.*  
   age of, 775, 860
- Meningitis, antibiotic combinations in, enterococcal, 1363
- Listeria monocytogenes*, 1363-1364
- Pseudomonas aeruginosa*, 1369  
   synergy of, 1401
- Menopause, hormone replacement therapy in. *See Hormone replacement therapy.*
- Menstrual cycle, 851-868  
   disorders of, amenorrhea. *See Amenorrhea.*  
   dysfunctional uterine bleeding, 855-859  
   dysmenorrhea, 852-855, 1015-1016  
   in eating disorders, 1046-1047  
   polycystic ovary syndrome, 865-866  
   normal, 851-852  
   onset of. *See Menarche.*
- 6-Mercaptopurine, in inflammatory bowel disease, 1112-1113
- Mesalamine, in inflammatory bowel disease, 1110-1111
- Metabolic equivalent, of physical activity, 354
- Metabolic syndrome, cardiac rehabilitation effects on, 258  
   in obesity, 363-385  
     diabetes mellitus in, 368-373  
     disorders associated with, 363  
     dyslipidemia in, 375-378  
     excess glucose production in, 371-372  
     experimental models of, 366-368  
     fatty acid metabolism and, 364-368  
     hyperinsulinemia in, 370-371  
     hypertension in, 373-375  
     insulin resistance in, 368-373  
     muscle metabolic disorders in, 368-370  
     pancreatic islet toxicity in, 372-373  
     versus fat distribution, 363-364, 366
- Metaplasia, gastric, *Helicobacter pylori* and, 1131-1132  
   intestinal, in esophagus. *See Barrett's esophagus.*
- Metastasis, of colorectal cancer, 1177-1178
- Metered-dose Inhalers, for asthma drug delivery, 831, 833, 839-841
- Methamphetamine abuse, in adolescents, 949
- Methimazole, hepatotoxicity of, 1297
- Methionine loading test, in hyperhomocysteinemia diagnosis, 218
- Methotrexate, hepatotoxicity of, 1301  
   in inflammatory bowel disease, 1113  
   in rheumatoid arthritis, 971
- Methylcellulose, in constipation, 1240-1241
- Methyldopa, hepatotoxicity of, 1300
- Methylprednisolone, in asthma, 836, 841
- Metronidazole, in bacterial vaginosis, 883  
   in *Helicobacter pylori* infections, 1127-1128  
   in inflammatory bowel disease, 1117, 1119

- in trichomoniasis, 881-882
- Microcomedones, 813
- Migraine headache, 842-845
- Mineral oil, in constipation, 1241
- Minocycline, hepatotoxicity of, 1294
  - in acne, 821-822
- Misoprostol, in NSAID-associated ulcers, 1335, 1338
- Molecular markers, for hereditary pancreatic adenocarcinoma, 721-732, 742-744
  - p16 gene mutations, 731-733
  - p53 gene mutations, 725, 727-730, 733
  - ras gene mutations, 721-726, 732, 743
  - SMAD4 gene mutations, 730-731, 733
- Moles, in familial atypical multiple mole melanoma syndrome, pancreatic adenocarcinoma and, 668-669
- Monoamine oxidase inhibitors, in depression, 901
- Monoclonal antibodies, in inflammatory bowel disease, 1114-1115, 1119
- Montelukast, in asthma, 837-838
- Mood disorders, in obesity, 393
- Morbid obesity, bariatric surgery for, 479-488
- Morning stiffness, in rheumatoid arthritis, 967-968
- Mortality, in obesity, 314-322
  - age and, 316-317
  - animal studies of, 314-315
  - body composition and, 318-322, 424
  - body mass index and, 315, 318-322, 424-426
  - body weight and, 315
  - ethnic effects in, 317-318
  - weight loss and, 320-322
- Motilin agonists, in irritable bowel syndrome, 1253
- Motor skills, of adolescents, sports injuries and, 986
- Moxifloxacin, 1452-1453
- MUC6 protein, in pancreatic ducts, in cystic fibrosis, 658
- Mucin, hypersecretion of, in cystic fibrosis, 661
- MUCLIN protein, in pancreatic ducts, in cystic fibrosis, 658
- Mucus, hypersecretion of, in pancreatic ducts, in cystic fibrosis, 658
- Müllerian agenesis, amenorrhea in, 862
- Muscles, abnormalities of, in insulin resistance, in obesity, 368-369
  - of adolescents, sports injuries and, 985-986
- Mycobacterial infections, fluoroquinolones in, 1457
- Mycophenolate mofetil, in inflammatory bowel disease, 1115
- Myocardial impairment, in eating disorders, 1044-1045
- Myocardial infarction, hypertension after. See *Hypertension, after myocardial infarction.*
  - smoking cessation after. See *Tobacco use.*
- Nabumetone, in rheumatoid arthritis, 971
- Nafarelin, in endometriosis, 854-855
- Nalidixic acid, 1451
  - chemical structure of, 1450
- Nasoenteric tubes, for enteral feeding, 1212-1214
- National Cancer Institute Physician-Delivered Smoking Cessation Program, 70
- National Cholesterol Education Program, hypercholesterolemia treatment guidelines of, 28-29
  - Step I and Step II diets of, 96-99
- National Heart, Lung, and Blood Institute, obesity guidelines of, 394
- National Institutes of Health, weight-loss diet guidelines of, 402-404
- National Weight Control Registry, 449-450
- NBC proteins, in pancreatic bicarbonate secretion, 650-651
- Nebulizers, for asthma drug delivery, 831, 833
- Necrosis-fibrosis sequence, in pancreatitis, 542-543
- Nedocromil, in asthma, 833, 835-836
- Neisseria gonorrhoeae infections, in adolescents, 874-879
- Nephrotic syndrome, hyperlipidemia in, 52
- Neurologic disorders, fluoroquinolone-induced, 1461-1462
- Neurotransmitters, deficiencies of, in depression, 897-898
- Neutropenia, febrile, antibiotic synergy in, 1401
- Nevi, in familial atypical multiple mole melanoma syndrome, pancreatic adenocarcinoma and, 668-669
- Nevirapine, hepatotoxicity of, 1296
- Nicotine, dependence on, 65-66
  - drug metabolism and, 66
  - inflammatory bowel disease and, 1117
  - physiologic effects of, 65-66
  - replacement of, in smoking cessation, 73-75, 283
  - withdrawal from, 65-66
- Nicotinic acid, hepatotoxicity of, 1299-1300
  - in hypercholesterolemia, 34-35
- Nissen fundoplication, in gastroesophageal reflux disease, 1148-1150
- Nitric oxide, vasorelaxing action of, free fatty acid effects on, 374-375
- Nitric oxide-containing nonsteroidal anti-inflammatory drugs, gastroduodenal effects of, 1340-1341

- Nitrofurantoin, hepatotoxicity of, 1294-1295
- Nizatidine, in gastroesophageal reflux disease, 1147
- Nonsteroidal anti-inflammatory drugs, gastrointestinal effects of, 1197-1198, **1329-1344**
- dyspepsia, 1333-1334
- epidemiology of, 1329
- hepatotoxicity, 1291-1293
- pathogenesis and pathology of, 1330-1332
- prevention of, 1336-1341
- risk factors for, 1332-1333
- ulcers, 1334-1341
- in rheumatoid arthritis, 970-971
- Noradrenergic theory, of mood disorders, 897-898
- Norflaxacin, 1451
- chemical structure of, 1450
- Norplant, 918
- Nosocomial pneumonia, fluoroquinolones in, 1455
- NSAIDs. *See Nonsteroidal anti-inflammatory drugs.*
- Nucleic acid amplification, in sexually transmitted disease testing, 887-888
- Nucleotides, in nutritional therapy, 1222
- Nutrition, **1209-1230**. *See also Diet.*
- as pharmacotherapy, 1222-1223
- assessment of, 1210-1211
- enteral, 1212-1215
- ethical use of, 1224-1225
- home administration of, 1223-1224
- in cancer, 1221-1222
- in pancreatitis, 1219-1220
- versus parenteral, 1217-1218
- ethical use of, 1224-1225
- home administration of, 1223-1224
- in cancer, 1221-1222
- in critical illness, 1221
- in inflammatory bowel disease, 1117-1118, 1218-1219
- in intensive care, 1221
- in kidney failure, 1220
- in liver disease, 1220
- in pancreatitis, 1219-1220
- parenteral, 1215-1217
- ethical use of, 1224-1225
- home administration of, 1223-1224
- in cancer, 1221-1222
- in inflammatory bowel disease, 1219
- in intensive care, 1221
- in kidney failure, 1220
- in pancreatitis, 1219-1220
- versus enteral, 1217-1218
- requirements for, 1211-1212
- withdrawal of, 1224-1225
- age and, 307-308, 316-317
- assessment of, 111-112
- body mass index and. *See Body mass index.*
- cancer in, 313-314
- cardiovascular disease and, 112-115, 257
- causes of, 388-389, 491-493
- childhood. *See Childhood obesity.*
- classification of, 305-306
- complications of, 388
- metabolic, **363-385**
- morbid, 478-479
- coronary artery disease in, 313, 319
- definition of, 305-306
- diabetes mellitus in, 311, 368-373
- dietary modification in, advantages of, 95
- antioxidants, 108-110
- lipid profile effects of, 100-108
- high-density lipoprotein cholesterol, 106-107
- low-density lipoprotein cholesterol, 101-106
- triglycerides, 107-108
- Step I and Step II diets for, 96-99
- vascular outcomes of, 99-100
- dyslipidemia in, 309-311, 375-378
- energy metabolism and. *See Energy balance; Energy expenditure; Energy intake.*
- environmental influences on, 335-343, 492-493
- ethnic differences in, 308-309
- energy expenditure and, 357
- mortality and, 317-318
- evaluation of, **387-399**, 454-455
- components of, 390
- goals of, 388-389
- history in, 390-393
- laboratory, 396-398
- organ system approach to, 395-396
- risk category determination in, 393-395
- sensitivity in, 398, 456-457
- gastroesophageal reflux disease in, 1145
- gender differences in, 306-307
- genetic influences on, 334-335, 356-357, 393
- history of weight gain in, 390-391
- hypertension in, 311-313, 373-375
- in adolescents, 773-774, 776
- in polycystic ovary syndrome, 865-866
- morbid, bariatric surgery for, 479-488
- complications of, 478-479
- definition of, 477-478
- morbidly in, 309-314
- mortality in. *See Mortality, in obesity.*
- osteoarthritis in, 313
- overview of, **305-332**
- parental, 356



- pathophysiology of, 112-113  
 perceptions of, 391  
 physician attitudes toward, 456  
 prevalence of, 306-309, 419-420, 477-478  
 prevention of, public health interventions for, **491-512**  
 psychosocial aspects of, 322-325, 392-393, 455  
 public health interventions for, **491-512**  
 respiratory disorders in, 314  
 risk factors in, 388  
 sleep apnea in, 314, 397-398  
 treatment of, 113-115  
   adherence to, 453-454  
   bariatric surgery in, **477-489**  
   behavioral. *See Behavioral therapy, for obesity.*  
   dietary. *See Diet, for weight loss.*  
   exercise in. *See Exercise and physical activity, in obesity.*  
   expectations for, 455  
   goals of, 455  
   in primary care, 454-457  
   motivation for, 389  
   multidisciplinary, 389  
   outcome of, 270-271  
   pharmacotherapy for. *See Drug(s), in obesity.*  
   public health interventions for, **491-512**  
   readiness for, 455  
   user-friendly facilities for, 398, 457-458  
   weight loss in. *See Weight loss.*  
 twin studies in, 334  
 Obsessive-compulsive disorder, 894  
 Occult blood testing, for colorectal cancer, 1169-1172  
   in diarrhea, 1266  
 Occupational therapy, for rheumatoid arthritis, 972-973  
 Octreotide, in hereditary pancreatitis, 526  
   in variceal bleeding, 1188  
 Ofloxacin, 1452  
   hepatotoxicity of, 1294  
   in gonorrhea, 875  
   in pelvic inflammatory disease, 1013  
 Oligomenorrhea, in polycystic ovary syndrome, 865-866  
 Olasalazine, in inflammatory bowel disease, 1111  
 Omeprazole, in gastroesophageal reflux disease, 1147-1148  
   diagnostic use of, 1144  
   in NSAID-associated dyspepsia, 1334  
   in NSAID-associated ulcers, 1335-1338  
   in peptic ulcer disease, 1186  
 Opioids, abuse of, in adolescents, 947  
   in diarrhea, 1273  
   in irritable bowel syndrome, 1253  
 Optifast diet, in obesity, 451  
 Oral contraceptives, 913-916  
   antibiotic interactions with 822  
   benefits of, 916  
   efficacy of, 914  
   emergency use of, 919-921  
   hepatotoxicity of, 1298-1299  
   in acne treatment, 823  
   in dysfunctional uterine bleeding, 858-859  
   in dysmenorrhea, 854  
   in irritable bowel syndrome, 1253  
   in polycystic ovary syndrome, 866  
   mechanism of action of, 913  
   pharmacology of, 914-915  
   progestin-only, 916  
   relative risks of, 922-923  
   side effects of, 915-916  
   types of, 913-914  
 Oral hypoglycemic agents, hepatotoxicity of, 1296-1297  
 Oral rehydration, for diarrhea, 1272  
 Orbofiban, in cardiovascular disease prevention, 170  
 Orlistat, in obesity, 451, 469-471  
 Orthostatic hypotension, in chronic fatigue syndrome, 847  
 Osgood-Schlatter disease, 970, 1003  
 Osteoarthritis, in obesity, 313  
 Osteochondritis dissecans, 1003-1004  
 Osteolysis, of clavicle, in sports, 993  
 Osteomyelitis, fluoroquinolones in, 1456-1457  
   *Pseudomonas aeruginosa*, antibiotic combinations in, 1369  
   staphylococcal, antibiotic combinations in, 1360-1361  
 Osteoporosis, in eating disorders, 1045-1046  
   in inadequate adolescent bone mass, 773  
   in inflammatory bowel disease, 1116-1117  
 Otitis externa, *Pseudomonas aeruginosa*, antibiotic combinations in, 1368-1369  
 Ovary, cysts of, 855, 1014  
   disorders of, pain in, 1013-1014  
   polycystic disease of, 865-866  
 Overgrowth syndrome, in rheumatoid arthritis, 969  
 Overlean persons, definition of, 306  
 Overuse injuries, in sports, 991-993  
 Overweight, definition of, 305-306, 394  
   prevalence of, 419-420  
 Oxygen-18 isotope, in energy expenditure measurement, 351-353  
 p16 protein, defects of, in familial atypical multiple mole melanoma syndrome, 668-669

- p16 protein (*Continued*)  
 in hereditary pancreatic adenocarcinoma, 692-693, 731-733
- p53 protein, defects of, in hereditary pancreatic adenocarcinoma, 725, 727-730, 733
- Pain, abdominal, diagnostic criteria for, 1314  
 in irritable bowel syndrome, 1247-1249  
 psychiatric disorders with, 1319-1320  
 chest, noncardiac, in gastroesophageal reflux disease, 1139  
 psychiatric disorders with, 1317-1319
- in fibromyalgia syndrome, 974-975  
 in hereditary pancreatitis, 520-521  
 in rheumatoid arthritis. *See Rheumatoid arthritis.*
- in sports injuries, clavicular osteolysis, 993  
 elbow, 996-997  
 gymnastics, 998-999  
 Little League shoulder, 996  
 lumbar spondylosis, 999-1000  
 Osgood-Schlatter disease, 1003  
 osteochondritis dissecans, 1003-1004  
 overuse, 992  
 patellofemoral syndrome, 1000-1002  
 shoulder impingement syndrome, 994-995  
 stress, 991  
 pelvic. *See Chronic pelvic pain.*
- Pancreas, adenocarcinoma of, hereditary.  
*See Hereditary pancreatic adenocarcinoma.*
- atypical ductal hyperplasia of, 707-708, 714
- autodigestion of, 549
- bicarbonate secretion in. *See Bicarbonate secretion, in pancreas.*
- cancer of, epidemiology of, 566  
 hereditary. *See Hereditary pancreatic adenocarcinoma.*  
 risk factors for, 566
- carcinoma of, endoscopic retrograde cholangiopancreatography in, 1072-1073  
 endoscopic ultrasonography in, 1075-1077
- ductal neoplasia of, 707-708. *See also Hereditary pancreatic adenocarcinoma.*  
 spectrum of, 691
- dysfunction of, in Johanson-Blizzard syndrome, 617  
 in Pearson's bone marrow syndrome, 617-618  
 in Shwachman-Diamond syndrome, 615-616  
 isolated enzyme deficiencies in, 618  
 immaturity of, 609  
 inflammation of. *See Hereditary pancreatitis; Pancreatitis.*  
 insufficiency of, 609  
 reserve capacity of, 609  
 sufficiency of, 609
- Pancreatectomy, in hereditary pancreatic adenocarcinoma, 715. *See also Hereditary pancreatic adenocarcinoma, surgical treatment of.*
- Pancreatic ducts, obstruction of, in cystic fibrosis, 613, 657-659
- Pancreatic islets, toxicity to, in obesity, 372-373
- Pancreatic juice, abnormal, in cystic fibrosis, 657-659  
 p53 gene mutation detection in, 727-728  
 ras gene mutation detection in, 725-726
- Pancreaticobiliary endoscopy, 1070-1074
- Pancreaticoduodenectomy, in hereditary pancreatic adenocarcinoma, 754-755
- Pancreatitis-associated gene, in hereditary pancreatitis, 542
- Pancreatitis, acute, nontrypsinogen mutations in, 541-542  
 trypsinogen activation in, 540-541, 549-563  
 alcoholic, cancer risk in, versus hereditary pancreatitis, 567-569  
 chronic, cancer risk in, 566  
 genetic testing in, 627-628  
 genetics of, 621-622  
 idiopathic, CFTR mutations in, 621-631  
 nontrypsinogen mutations in, 541-542  
 pathophysiology of, 542-543  
 endoscopic ultrasonography of, 1079  
 familial, versus hereditary pancreatitis, 519  
 hereditary. *See Hereditary pancreatitis.*  
 in cystic fibrosis. *See Cystic fibrosis.*  
 nutrition in, 1219-1220
- Panic attacks, 893-895
- Panic disorder, in esophageal motility disorders, 1317-1319  
 in irritable bowel syndrome, 1316
- Pantoprazole, in gastroesophageal reflux disease, 1147-1148
- Pap smears, in adolescents, 886-887
- Parenteral nutrition. *See under Nutrition.*
- Parkinsonism, treatment of, hepatotoxicity in, 1290
- Patellofemoral syndrome, 1000-1002
- PCP (phencyclidine) use, in adolescents, 947-948
- Peak expiratory flow monitoring, in asthma, 831
- Pearson's bone marrow syndrome, 617-618
- Pediatric patients, constipation in, 1233-1234

- genetic testing in, for hereditary pancreatic disease, 580, 585  
obesity in. See *Childhood obesity*.  
pancreatic dysfunction in, 610. See also *Cystic fibrosis*.
- Pelvic examination, in amenorrhea, 863-864  
in chronic pelvic pain, 1017-1018  
in dysmenorrhea, 853
- Pelvic inflammatory disease, 876-879  
chlamydial, 873-874, 876-879  
diagnosis of, 1010-1011  
dysmenorrhea in, 853  
pain in, 1009-1012  
risk factors for, 873, 1010  
treatment of, 1012-1013
- Pelvic pain, chronic. See *Chronic pelvic pain*.
- Pemoline, hepatotoxicity of, 1289
- Penicillamine, hepatotoxicity of, 1303
- Penicillin(s), hepatotoxicity of, 1294  
in syphilis, 880  
synergy of, clinical uses for, 1399-1400
- Pentasa, in inflammatory bowel disease, 1111
- Peptic ulcer disease, bleeding in, 1184-1187  
endoscopic management of, 1060  
NSAID-associated, prevention of, 1336-1341  
treatment of, 1334-1335
- Percutaneous endoscopic gastrostomy, for enteral feeding, 1213-1214
- Performance anxiety, 892
- Perinuclear antineutrophil cytoplasmic antibodies, in inflammatory bowel disease, 1109
- Periodontal disease, atherosclerosis and, 139-141
- Peripheral vascular disease, in hyperhomocysteinemia, 224-225
- Personal fables, of adolescents, 791
- Peutz-Jeghers syndrome, pancreatic cancer and, 670
- pH, in premature trypsinogen activation, in acute pancreatitis, 557-560  
monitoring of, in gastroesophageal reflux disease, 1142-1144
- Pharmacodynamics, of antibiotics. See *Antibiotics, pharmacodynamics of*.
- Phencyclidine use, in adolescents, 947-948
- Phenolphthalein, in constipation, 1242
- Phentermine, in obesity, 450-453, 466-467
- Phenylpropanolamine, in obesity, 464
- Phenytoin, hepatotoxicity of, 1288
- Phobias, 893-894  
in esophageal motility disorders, 1317-1319
- Photodynamic therapy, endoscopic, 1065
- Phototoxicity, of fluoroquinolones, 1460-1461
- Physal injuries, 987-991
- Physical activity. See *Exercise and physical activity*.
- Physical therapy, for rheumatoid arthritis, 972-973
- Piperacillin, synergy of, 1398
- Pirbuterol, in asthma, 840
- Pitching injuries, of arm, 996-997
- Plaque hybridization assay, in *ras* gene mutation detection, in hereditary pancreatic adenocarcinoma, 724
- Platelet disorders, in hyperhomocysteinemia, 228-229
- Plugged duct theory, in pancreatitis, 542-543
- Pneumonia, aspiration, in enteral feeding, 1214-1215  
fluoroquinolones in, 1453-1455  
*Legionella pneumophila*, antibiotic combinations in, 1366-1367
- Podofilox, in condylomata acuminata, 887
- Podophyllin, in condylomata acuminata, 887
- Polycystic ovary syndrome, 865-866
- Polyethylene glycol, in constipation, 1241
- Polymerase chain reaction, for gene mutation detection, in hereditary pancreatic adenocarcinoma, *p16* gene, 731  
*p53* gene, 728  
*ras* gene, 722-726  
trypsinogen, 535  
for hepatitis C virus, 1088  
for sexually transmitted disease diagnosis, 887-888
- Polyps, colorectal. See *Colorectal polyps*.
- Porphyria cutanea tarda, hemochromatosis in, 1094
- Portal hypertension, esophageal varices in, 1187-1190
- Portosystemic shunt, for variceal bleeding, 1188, 1190
- Positron emission tomography, of hereditary pancreatic adenocarcinoma, 753
- Post-traumatic stress disorder, 894
- Pouchitis, in inflammatory bowel disease, 1116
- Prealbumin levels, in nutritional assessment, 1211
- Prednisolone, in asthma, 836, 841
- Prednisone, in asthma, 838, 841  
in inflammatory bowel disease, 1119
- Pregnancy, in adolescents, amenorrhea in, 860, 863  
ectopic, pain in, 1014  
prevention of. See *Contraception; Oral contraceptives*.  
statistics on, 907-898  
uterine bleeding in, 855-859

- Prevention, of cardiovascular disease. See *Cardiovascular disease, risk factor modification for.*
- Primary biliary cirrhosis, 1095-1096
- Progesterone challenge test, in amenorrhea, 864
- Progestins, in dysfunctional uterine bleeding, 858-859  
in oral contraceptives. See *Oral contraceptives.*
- Prognostic nutritional index, 1211
- Prolactin, measurement of, in amenorrhea, 864
- Propafenone, hepatotoxicity of, 1300
- Propionibacterium acnes*, in acne, 812, 822
- Propylthiouracil, hepatotoxicity of, 1297
- Prostaglandin(s), in dysmenorrhea, 852-853, 1015-1016  
inhibitors of, in dysmenorrhea, 854, 1016  
NSAID inhibition of, gastropathy in, 1331-1332
- Prosthetic valve endocarditis, antibiotic combinations in, 1360
- Protein, dietary requirements of, determination of, 1212  
energy content of, 348  
energy density of, 405-406  
metabolism of, 349  
storage of, 349
- Protein C, homocysteine interference with, 228
- Proton-pump inhibitors, in Barrett's esophagus, 1156-1157  
in gastroesophageal reflux disease, 1144, 1147-1148  
in *Helicobacter pylori* infections, 1125-1130, 1132  
in NSAID-associated dyspepsia, 1334  
in NSAID-associated ulcers, 1335-1338  
in peptic ulcer disease, 1185-1186  
in variceal bleeding, 1188
- Proxycrine effect, in hereditary pancreatic adenocarcinoma, 698
- PRSS1 gene, mutations of, 532-535  
hereditary pancreatitis in, 537  
screening for, 535-537  
terminology of, 532
- Pseudomonas* infections, antibiotic combinations in, 1367-1369, 1400-1401
- Psychologic and psychiatric aspects, of chronic pelvic pain, 1016-1017, 1021-1023  
of eating disorders, 1040-1041  
of gastrointestinal disease, **1313-1327**  
abdominal pain, 1319-1320  
abuse and, 1321-1322  
diagnostic criteria and, 1313-1315  
dyspepsia, 1320-1321  
esophageal motility disorders, 1317-1319  
irritable bowel syndrome, 1251-1252, 1254, 1315-1317  
treatment of, 1322-1323  
of obesity, 322-325, 392-393, 455  
of smoking cessation, 71-73  
of sports injuries, 988-989
- Psychotherapy, for depression, 900-901
- Psyllium, in constipation, 1240-1241
- Puberty, 771-774  
constitutional delay of, amenorrhea in, 862  
normal age for, 851  
precocious, 851-852
- Pubic hair, development of, 772
- Public health interventions, for obesity prevention and treatment, **491-512**  
causes and, 491-493  
childhood, 494-496  
community-based, 502-504  
environmental studies in, 505  
future directions in, 505-507  
school-based, 496-501  
steps for, 506-507  
worksite-based, 501-502
- Quality of life, bariatric surgery decisions and, 486-487  
cardiac rehabilitation effects on, 258-260  
Quetelet's index. See *Body mass index.*
- Quinidine, hepatotoxicity of, 1300
- Quinolones. See *Fluoroquinolones.*
- Quinupristin-dalfopristin, in enterococcal infections, 1485-1486  
synergy of, 1397
- RAAFFT screening tool, for substance abuse, 952
- Rabeprazole, in gastroesophageal reflux disease, 1147-1148
- Radiation therapy, for colorectal cancer, 1177-1178  
for hereditary pancreatic adenocarcinoma, 756-757
- Radionuclide scan, in gastrointestinal bleeding, 1194-1195
- Radiopaque marker studies, in constipation, 1235-1238
- Raniditine, in gastroesophageal reflux disease, 1147  
in *Helicobacter pylori* infections, 1127  
in NSAID-associated ulcers, 1335
- ras gene mutations, in hereditary pancreatic adenocarcinoma, 692-693, 713, 721-726, 732
- Rectoceles, 1245
- Rectum. See *Anorectum; Colorectal cancer.*

- Reflux, acid. See *Gastroesophageal reflux disease*.
- Refractory sideroblastic anemia, in Pearson's bone marrow syndrome, 617-618
- Reg protein, in pancreatic duct plugs, in cystic fibrosis, 658
- Regurgitation, in gastroesophageal reflux disease, 1140
- Rehabilitation, cardiac. See *Cardiac rehabilitation*.
- in rheumatoid arthritis, 972-973
- Rehydration, for diarrhea, 1272
- Residuals, in enteral feeding, 1214
- Resistance, antibiotic. See *Antibiotics, resistance to*.
- insulin. See *Insulin resistance*.
- Respiratory disorders, in obesity, 314, 364, 397-398
- Respiratory gas studies, in energy expenditure measurement, 351
- Resting metabolic rate, 348
- factors affecting, 353-355
- Restriction fragment length polymorphism analysis, in *ras* gene mutation detection, 722-726
- in trypsinogen mutation detection, 535
- Retinoids, in acne, 820-821
- Rheumatoid arthritis, juvenile, 967-974
- clinical features of, 968-970
- diagnostic criteria for, 968
- extended oligoarticular, 969
- late-onset, 970
- pauciarticular, 969-970
- polyarticular, 969
- systemic, 968-969
- treatment of, 970-974
- Ribavirin, in hepatitis C, 1088-1089
- Ribosomal RNA amplification, in sexually transmitted disease testing, 887-888
- Rifampin, hepatotoxicity of, 1296
- Riluzole, hepatotoxicity in, 1290
- Ring gastroplasty, in obesity, 483-484
- Risk modification, in cardiovascular disease. See *Cardiovascular disease, risk factor modification for*.
- Ritonavir, hepatotoxicity of, 1296
- Rofecoxib, gastroduodenal effects of, 1339-1340
- in rheumatoid arthritis, 970-971
- Rokitansky-Küster-Hauser syndrome, amenorrhea in, 862
- Rome diagnostic criteria, for constipation, 1231
- for functional abdominal pain, 1314
- for functional dyspepsia, 1314-1315
- for irritable bowel syndrome, 1247, 1314
- Rotator cuff impingement syndrome, in sports, 994-995
- Saccharomyces cerevisiae* antibody, in inflammatory bowel disease, 1109
- Salicylates, hepatotoxicity of, 1291
- Salicylic acid, in acne, 821
- Salmeterol, in asthma, 833, 836, 838
- Salter-Harris classification, of physeal injuries, 989-990
- Scarring, in acne, 814
- School support, for rheumatoid arthritis, 973-974
- for risky behavior problems, 806
- for substance abuse prevention, 957-959
- Sclerosing cholangitis, endoscopic retrograde cholangiopancreatography in, 1073-1074
- Sclerotherapy, for peptic ulcer bleeding, 1186
- for variceal bleeding, 1061, 1189
- Sebum, secretion of, in acne, 812
- Second messengers, in pancreatic bicarbonate secretion, 643
- Secretin, in pancreatic bicarbonate secretion, 641-642
- Sedative abuse, in adolescents, 948-949
- Sedentary activities, obesity and, 337-338
- Segregation analysis, in hereditary pancreatic adenocarcinoma, 681-682, 687
- Selective cyclooxygenase-2 inhibitors, gastroduodenal effects of, 1339-1340
- Selective serotonin-reuptake inhibitors, in anxiety, 897
- in depression, 901
- in irritable bowel syndrome, 1253
- Self-monitoring, in obesity, of diet, 444-445
- of physical activity, 430-431
- Senna, in constipation, 1241
- Septohippocampal system, anxiolytic drug action on, 893
- Serotonin, abnormalities of, in fibromyalgia syndrome, 976
- antagonists of, in irritable bowel syndrome, 1253
- Serotonergic theory, of mood disorders, 898
- Serratia* infections, antibiotic combinations in, 1371-1372
- Sever's disease, 1005
- Sexual activity, in adolescents, 777-778
- contraception for. See *Contraception; Oral contraceptives*.
- disease transmission in. See *Sexually transmitted diseases*.
- education on, 801-807
- media influence on, 799
- statistics on, 794-795, 907
- Sexual appeal, anxiety about, 892
- Sexual characteristics, development of, 772
- Sexually transmitted diseases, in adolescents, 869-889

- Sexually transmitted diseases (*Continued*)  
 bacterial vaginosis, 882-883  
 biologic factors in, 872-873  
*Chlamydia trachomatis*, 873-874,  
 876-879  
 confidentiality issues in, 872  
 epidemiology of, 869  
 ethnic issues in, 872  
 health care access and, 871-872  
 herpes simplex virus, 883-885  
 human papillomavirus, 885-887  
*Neisseria gonorrhoeae*, 874-879  
 overview of, 869-870  
 pelvic inflammatory disease. *See Pelvic inflammatory disease.*  
 protection against, 870-871  
 psychosocial issues in, 870-871  
 racial issues in, 872  
 syphilis, 879-881  
 tests for, 887-888  
*Trichomonas vaginalis*, 881-882  
 Short bowel syndrome, diarrhea in,  
 1268-1269  
 Short stature, in Shwachman-Diamond  
 syndrome, 616  
 Shoulder, Little Leaguer's, 996  
 Shoulder impingement syndrome, in  
 sports, 994-995  
 Shunts, for variceal bleeding, 1188-1190  
 Shwachman-Diamond syndrome, clinical  
 features of, 615-617  
 Sibrafiban, in cardiovascular disease  
 prevention, 170-171  
 Sibutramine, in obesity, 451-452, 467-469,  
 471, 473  
 Sideroblastic anemia, refractory, in  
 Pearson's bone marrow syndrome,  
 617-618  
 Sigmoidoscopy, 1068-1070  
   in colorectal cancer and polyps, 1168,  
   1170-1172  
   in constipation, 1234-1235  
   in diarrhea, 1263, 1268  
   in gastrointestinal bleeding, 1195-1196  
 Skin disorders, fluoroquinolone-induced,  
 1460-1461  
 Sleep apnea, in obesity, 314, 364, 397-398  
 Sleep disorders, in fibromyalgia syndrome,  
 974, 976, 978  
 SMAD4 gene mutations, in hereditary  
 pancreatic adenocarcinoma, 730-731,  
 733  
 Small bowel bypass, in obesity, 482-483  
 Small intestine, bleeding from, 1190-1191  
   endoscopy of, 1065, 1068  
 Smoking. *See Tobacco use.*  
 Smooth muscle, homocysteine interactions  
 with, 228  
 Social acceptance, anxiety about, 892  
 Social cognitive theory, of behavior, 427  
 Social phobias, 893-894  
 Sociocultural issues, in adolescence,  
 775-777  
 Sodium, in pancreatic bicarbonate  
 secretion, 644-645  
 Sodium-potassium-chloride cotransporter,  
 in pancreatic bicarbonate secretion,  
 651-652  
 Sodium:bicarbonate cotransport, in  
 pancreatic bicarbonate secretion,  
 646-651  
 Solvent huffing, in adolescents, 932, 948  
 Somatization disorder, in esophageal  
 motility disorders, 1317-1319  
 Sonde enteroscopy, 1191  
 Sorbitol, in constipation, 1241  
 Soy protein, low-density lipoprotein levels  
 and, 105  
 Sparfloxacin, 1452  
 Spasm, coronary artery, in smoking, 65  
 Spectroscopy, tissue, in inflammatory  
 bowel disease, 1108-1109  
 Spermicides, 913  
 Sphincterotomy, in hereditary pancreatitis,  
 526  
 Spine, sports injuries of, 999-1000  
 Spironolactone, in acne, 823  
   in polycystic ovary syndrome, 866  
 Spondylosis, lumbar, in sports, 999-1000  
 Sports injuries, in adolescents, **983-1007**  
   bone development and, 988  
   classification of, 984  
   clavicular osteolysis, 993  
   definition of, 983  
   elbow, 996-997  
   epidemiology of, 983-984  
   growth cartilage and, 987-988  
   growth considerations in, 985-987  
   gymnast's wrist, 998-999  
   Little League shoulder, 996  
   lumbar spondylosis, 999-1000  
   maturity considerations in, 985-987  
   Osgood-Schlatter disease, 1003  
   osteochondritis dissecans, 1003-1004  
   overuse, 991-993  
   patellofemoral syndrome, 1000-1002  
   physeal, 989-991  
   prevention of, 1005  
   psychology of, 988-989  
   Sever's disease, 1004  
   shoulder impingement syndrome,  
     994-995  
   stress, 991, 993  
   throwing, 996-997  
 Staging, of colorectal cancer, 1176-1177  
   of pancreatic adenocarcinoma, 750-753  
 Staphylococcal infections, antibiotic  
 combinations in, 1358-1361, 1400  
 Stapling, gastric, in obesity, 483-484  
 Starvation, in eating disorders. *See Eating disorders.*

- Statins, hepatotoxicity of, 1299  
     in hypercholesterolemia, 31-33, 289-293  
 Steatohepatitis, nonalcoholic, 1089-1092  
 Steatorrhea, 1270-1272  
 Stein-Leventhal (polycystic ovary) syndrome, 865-866  
 Stents, for gastrointestinal obstruction, endoscopic placement of, 1063-1064, 1066-1067  
 Sterols, plant, in low-density lipoprotein lowering, 102  
 Still's disease, 968-969  
 Stimulant laxatives, in constipation, 1241  
 Stimulants, hepatotoxicity of, 1289  
 Stomach, bariatric surgery on. *See Bariatric surgery.*  
     cancer of, *Helicobacter pylori* infections and, 1131  
     Mallory-Weiss tears of, bleeding from, 1187  
     metaplasia of, *Helicobacter pylori* infections and, 1131-1132  
 Stool, examination of, in diarrhea, 1266  
 Streptococcal infections, antibiotic combinations in, 1361-1362, 1401  
*Streptococcus pneumoniae*, antibiotic pharmacodynamics and, 1440-1444  
 Streptogramins, synergy of, 1396-1397  
 Stress, emotional, chronic pelvic pain in, 1021-1023  
     post-traumatic stress disorder after, 894  
     gastroesophageal reflux disease in, 1145  
     in irritable bowel syndrome, 1251  
     physical, sports injuries in, 991, 993  
 Stroke, in hyperhomocysteinemia, 224  
 Subjective global assessment, of nutritional status, 1211  
 Substance abuse. *See also Alcohol use.*  
     in adolescents, 777, 927-966  
     assessment of, 950-955  
     consequences of, 941-950  
     definition of, 927-928  
     developmental factors in, 932-934  
     epidemiology of, 928-932  
     media influence on, 799-801, 937-938  
     predictive factors for, 939-940  
     prevention of, 801-807, 956-960  
     preventive solutions for, 795-796, 799-802, 956-960  
     protective factors in, 938-939  
     risk factors for, 934-938  
     stages of, 927-928  
     statistics on, 795-796  
     treatment of, 955-956  
 Sucralfate, in NSAID-associated ulcers, 1334-1336  
 Suicide, in adolescents, causes of, 777  
     in depression, 900, 902  
 Sulbactam, synergy of, 1398  
 Sulfasalazine, hepatotoxicity of, 1295  
     in inflammatory bowel disease, 1110-1111  
     in rheumatoid arthritis, 971  
 Sulfonamides, hepatotoxicity of, 1295  
 Sulfonylureas, hepatotoxicity of, 1297  
 Sulindac, hepatotoxicity of, 1291-1292  
 Surgery, bariatric. *See Bariatric surgery.*  
 Susceptibility, to antibiotics, 1409-1411. *See also Antibiotics, resistance to.*  
 Sweat gland dysfunction, in cystic fibrosis, 597-598, 602  
 Swimmer's shoulder, 994-995  
 Sympathetic nervous system, altered response of, in fibromyalgia syndrome, 976  
     overactivity of, in metabolic syndrome, 375  
 Syndrome X. *See Metabolic syndrome.*  
 Synergy, antibiotic. *See Antibiotics, synergy of.*  
 Syphilis, in adolescents, 879-881  
 Tacrine, hepatotoxicity of, 1290  
 Tacrolimus, in inflammatory bowel disease, 1115  
 Tamoxifen, hepatotoxicity of, 1299  
 Tanner stage, in sexual development, 772  
 Tazarotene, in acne, 820-821  
 Tazobactam, synergy of, 1398  
 Team approach, to eating disorders, 1041-1042  
     to rheumatoid arthritis, 970  
 Technetium 99m scan, in gastrointestinal bleeding, 1194-1195  
 Teicoplanin, in enterococcal infections, 1482-1484  
     synergy of, clinical uses for, 1400  
 Telangiectasia-ataxia, pancreatic cancer and, 670  
 Temafloxacin, 1452, 1462-1463  
 Tender points, in fibromyalgia syndrome, 974-975  
 Tension headache, 842  
 Terbutaline, in asthma, 840  
 Terfenadine, hepatotoxicity of, 1303  
 Testicular feminization, amenorrhea in, 862  
 Testosterone, secretion of, in puberty, 771-772  
 Tetracycline, hepatotoxicity of, 1294  
     in acne, 821  
     in *Helicobacter pylori* infections, 1127-1128  
 Thalidomide, in inflammatory bowel disease, 1115  
 Theophylline, in asthma, 835, 837  
 Thermic effects, of food intake, 348-349, 354  
 Sulfasalazine, hepatotoxicity of, 1295  
     in inflammatory bowel disease, 1110-1111  
     in rheumatoid arthritis, 971  
 Sulfonamides, hepatotoxicity of, 1295  
 Sulfonylureas, hepatotoxicity of, 1297  
 Sulindac, hepatotoxicity of, 1291-1292  
 Surgery, bariatric. *See Bariatric surgery.*  
 Susceptibility, to antibiotics, 1409-1411. *See also Antibiotics, resistance to.*  
 Sweat gland dysfunction, in cystic fibrosis, 597-598, 602  
 Swimmer's shoulder, 994-995  
 Sympathetic nervous system, altered response of, in fibromyalgia syndrome, 976  
     overactivity of, in metabolic syndrome, 375  
 Syndrome X. *See Metabolic syndrome.*  
 Synergy, antibiotic. *See Antibiotics, synergy of.*  
 Syphilis, in adolescents, 879-881  
 Tacrine, hepatotoxicity of, 1290  
 Tacrolimus, in inflammatory bowel disease, 1115  
 Tamoxifen, hepatotoxicity of, 1299  
 Tanner stage, in sexual development, 772  
 Tazarotene, in acne, 820-821  
 Tazobactam, synergy of, 1398  
 Team approach, to eating disorders, 1041-1042  
     to rheumatoid arthritis, 970  
 Technetium 99m scan, in gastrointestinal bleeding, 1194-1195  
 Teicoplanin, in enterococcal infections, 1482-1484  
     synergy of, clinical uses for, 1400  
 Telangiectasia-ataxia, pancreatic cancer and, 670  
 Temafloxacin, 1452, 1462-1463  
 Tender points, in fibromyalgia syndrome, 974-975  
 Tension headache, 842  
 Terbutaline, in asthma, 840  
 Terfenadine, hepatotoxicity of, 1303  
 Testicular feminization, amenorrhea in, 862  
 Testosterone, secretion of, in puberty, 771-772  
 Tetracycline, hepatotoxicity of, 1294  
     in acne, 821  
     in *Helicobacter pylori* infections, 1127-1128  
 Thalidomide, in inflammatory bowel disease, 1115  
 Theophylline, in asthma, 835, 837  
 Thermic effects, of food intake, 348-349, 354

- Thiazolidinediones, hepatotoxicity of, 1297
- Thromboembolic disease, in hormone replacement therapy, 189-190  
in hyperhomocysteinemia, 225  
promotion of, smoking in, 64-65
- Thrombolytic therapy, for myocardial infarction, hemorrhage risk in, 2-3
- Throwing injuries, of arm, 996-997
- Thyroid gland, insufficiency of, hyperlipidemia in, 51-52
- Ticarcillin, synergy of, 1398
- Ticlopidine, hepatotoxicity of, 1300  
in cardiovascular disease prevention, 167-168
- Tissue ablation, endoscopic, 1064-1065
- Tissue spectroscopy, in inflammatory bowel disease, 1108-1109
- Tobacco use, 63-80  
cardiovascular effects of, 64-65, 268  
in diabetes mellitus, 90  
cessation of, behavior interventions for, 71-73  
coronary artery disease risk in, 64  
cost-effectiveness of, 282-283  
health care provider role in, 66-68  
multicomponent interventions for, 76-77  
pharmacotherapy for, 73-76  
psychological interventions for, 71-73  
readiness for change and, 68-70  
results of, 268  
drug metabolism and, 66  
hereditary pancreatic adenocarcinoma and, 686  
in adolescents, 777  
consequences of, 943-944  
developmental issues in, 932-934  
media influence on, 799-801, 937-938  
predictive factors for, 939-940  
protective factors for, 938-939  
risk factors for, 934-938  
statistics on, 795-796, 929-930  
inflammatory bowel disease and, 1117  
nicotine effects in, 64-66
- Tobramycin, pharmacodynamics of, 1438
- Tocopherol (vitamin E), cardiovascular effects of, 108-109, 242-246
- Tolcapone, hepatotoxicity of, 1290
- TPN. See *Nutrition, parenteral*.
- Transforming growth factors, in hereditary pancreatic adenocarcinoma, 698-699
- Transitional therapy, with antibiotics, 1457-1460
- Transjugular intrahepatic portosystemic shunt, for variceal bleeding, 1188, 1190
- Transplantation, hyperhomocysteinemia in, 220  
hyperlipidemia in, 54-55  
liver, 1096-1100  
in primary biliary cirrhosis, 1095  
in steatohepatitis, 1092
- Transtheoretical model of behavior change, of behavior, 427
- Transtheoretical Model of Change, in smoking cessation, 68-70
- Treponema pallidum* infections, in adolescents, 879-881
- Tretinoin, in acne, 820
- Triamcinolone, in asthma, 839  
in rheumatoid arthritis, 972
- Trichomonas vaginalis* infections, in adolescents, 881-882
- Triglycerides, excess of. See *Hypertriglyceridemia*.  
hydrolysis of, free fatty acid formation in, 365
- Trimethoprim-sulfamethoxazole, hepatotoxicity of, 1294  
synergy of, 1394-1395
- Troglitazone, hepatotoxicity of, 1297
- Tropisetron, in fibromyalgia syndrome, 979
- Trovafloxacin, 1452  
chemical structure of, 1450  
hepatotoxicity of, 1294
- Trypsin, inhibitors of, in hereditary pancreatitis, 526
- Trypsinogen, activation of, in acute pancreatitis, 549-563  
calcium in, 557-560  
cathepsin B knock-out model for, 555-557  
clinical studies of, 551-553  
initiation of, in acinar cells, 550-551  
intracellular activation compartment, 553-555  
lysosomal enzymes in, 555  
pH and, 557-560  
in hereditary pancreatitis, 525  
anionic, structure of, 533  
versus cationic, 534  
cationic, activation of, in acute pancreatitis, 540-541  
defects of, 532  
cancer in, 693  
codon 16 mutation in, 539  
codon 23 K23R mutation in, 539  
codon 29 mutation in, 538-539  
codon 122 mutation in, 537-538  
hereditary pancreatitis in, 537  
features of, 532-534  
gene of. See *PRSS1* gene.  
structure of, 533  
versus anionic, 534  
defects of, 532, 552-553  
deficiency of, in pancreatic dysfunction, 618  
terminology of, 532
- Trypsinogen activation peptide, in pancreatitis, 551
- Tuberculosis, treatment of, hepatotoxicity in, 1295-1296



- Tubes, feeding, for enteral feeding, 1212-1214
- Tumor(s), brain, headache in, 842
- subepithelial, of gastrointestinal tract, endoscopic ultrasonography of, 1079
- Tumor markers, for hereditary pancreatic adenocarcinoma, 742-744, 753
- Tumor necrosis factor- $\alpha$ , antibodies to, in inflammatory bowel disease, 1114
- overexpression of, in obesity, 369-370
- Tumor suppressor genes, mutations of, in hereditary pancreatic adenocarcinoma, 692-693
- Turner's syndrome, amenorrhea in, 861
- Ulcer(s), peptic. *See Peptic ulcer disease.*
- Ulcerative colitis. *See Inflammatory bowel disease.*
- Ultrasonography, with endoscopy, 1075-1079
- in celiac neurolysis, 1077
- in choledocholithiasis, 1078-1079
- in esophageal cancer, 1077-1078
- in hereditary pancreatic adenocarcinoma, 710-713, 720, 751
- in inflammatory bowel disease, 1108-1109
- in pancreatic cancer, 1075-1077
- in pancreatitis, 1079
- Urethritis, chlamydial, 873-874
- Urinary tract, disorders of, pain in, 1015, 1021
- infections of, fluoroquinolones in, 1456
- Ursodeoxycholic acid, in primary biliary cirrhosis, 1095-1096
- Uterus, cancer of, in obesity, 314
- dysfunctional bleeding from, 855-859
- Uveitis, in rheumatoid arthritis, 969-970
- Vagal stimulation, in pancreatic bicarbonate secretion, 642-643
- Vaginal bleeding, dysfunctional, 855-859
- Valproic acid, hepatotoxicity of, 1288-1289
- Valvular heart disease, fen-phen-induced, 466-467
- Vancomycin, resistance to, in enterococcal infections, 1478, 1482-1487
- synergy of, 1395-1396
- clinical uses for, 1400
- Vanishing bile duct syndrome, drug-induced, 1282
- Variceal bleeding, esophageal, treatment of, 1061, 1187-1190
- Vascular endothelial growth factor, promotion of, gene therapy in, 208-209
- Vascular injury, of liver, drug-induced, 1283, 1285-1286
- Vasoactivity, of free fatty acids, 374-375
- Vasopressin, in gastrointestinal bleeding, 1198-1199
- in variceal bleeding, 1188-1189
- Violence, in adolescents, 792-794
- media influence on, 797-798
- prevention of, 801-807
- Viral hepatitis, 1085-1089
- Viral vectors, for gene therapy, for cardiovascular disease, 199-203
- Virilization, amenorrhea with, 864
- Virtual colonoscopy, 1070
- Visceral hypersensitivity, in irritable bowel syndrome, 1250
- Vitamin(s), in colorectal cancer prevention, 1166
- Vitamin B<sub>12</sub>, hyperhomocysteinemia and, 226, 229-230
- Vitamin C, cardiovascular effects of, 110, 239-241
- Vitamin E, cardiovascular effects of, 108-109, 242-246
- Vomiting, in bulimia nervosa, 1029
- Waist/hip circumference ratio, measurement of, 395-396
- risks associated with, 394
- versus mortality, 319, 425-426
- Warfarin, hepatotoxicity of, 1300
- in cardiovascular disease prevention, 172-174, 271
- Warts, genital, 885-887
- Water, in food, energy density effects of, 406-407, 410
- Weight, excessive. *See Obesity.*
- maintenance of, diet for, 403-404, 411-412
- physical activity for, 422-423
- of adolescents, sports injuries and, 985
- regulation of, patient understanding of, 391
- versus mortality, 315
- Weight gain, after obesity treatment, 448
- drug-induced, 393
- history of, 390-391
- prevention of, 412-413
- community programs for, 504
- physical activity in, 422
- Weight loss, after bariatric surgery, 480-481
- in eating disorders. *See Eating disorders.*
- in gastroesophageal reflux disease, 1145
- in obesity, dietary approach to. *See Diet, for weight loss.*
- expectations of, 391-392, 446
- in behavioral treatment, 446-450

Weight loss (*Continued*)

- interventions for, 421. See also *Bariatric surgery*; *Diet*; *Drug(s)*, in obesity; *Exercise and physical activity*.
- mortality and, 320-322
- response to, 391
- nutritional assessment in, 1210-1211
- Whipple procedure, for pancreatic resection, in hereditary pancreatic adenocarcinoma, 754-755
- Whiteheads, 813
- Worksites, obesity prevention and treatment programs in, 501-502
- Wrist, gymnast's, 998-999

- Xemilofiban, in cardiovascular disease prevention, 170

- Zafirklast, hepatotoxicity of, 1303
- Zafirlukast, in asthma, 835, 837
- Zamifenacin, in irritable bowel syndrome, 1252
- Zileuton, in asthma, 835, 837
- Ziracin, in enterococcal infections, 1486
- Zymogens. See also *Trypsinogen*.
- secretion of, 549
- synthesis of, 550-551

